

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 21084

FolderID:

Folder Title:
12th World AIDS Conference [binder]

Stack:

S

Row:

66

Section:

6

Shelf:

7

Position:

3

 12th World AIDS Conference

12th
World AIDS
Conference

June 28-July 3, 1998
Geneva, Switzerland

Mr. Todd Summers

MEDIA ADVISORY



12th World AIDS
Conference Geneva
June 28 – July 3 1998

FOR IMMEDIATE RELEASE
October, 1997

Contact: Jacqueline Franchetti
Ogilvy, Adams & Rinehart, New York
+1 212 880-5231

Swiss Media: Michel Zbinden
Farner Teuber Communications, Lausanne
+ 41 21 729 1222

12TH WORLD AIDS CONFERENCE ANNOUNCES CALL FOR ABSTRACTS

– Geneva to Host World's Foremost AIDS Conference; Focus on "Bridging The Gap" –

Geneva, Switzerland – The 12th World AIDS Conference today issued a call for abstracts to AIDS researchers, physicians, community leaders and policy makers around the world. The Conference, to be held June 28 to July 3, 1998, at the Palexpo Conference Centre in Geneva, will feature the most significant developments in the field of AIDS research, and focus international attention on the urgent need to bridge the gaps between developed and developing countries, where more than 90% of people with HIV live.

"In addition to scientific exchange, an important goal of the Conference, indeed the Conference theme, is to 'bridge the gap' in the response to AIDS between the developed and developing world," said Bernard Hirschel, Chair of the Conference and head of the HIV/AIDS section of the Cantonal Universitaire Hospital in Geneva. "Geneva, an international crossroads, is a highly appropriate city to host the Conference. Home to prestigious health institutions, including UNAIDS and WHO, Geneva has a long history of forging solutions to complex international problems."

Conference organisers estimate that close to 6,000 abstracts will be submitted, covering the latest scientific progress in AIDS treatment and vaccine development, as well as important research in the areas of AIDS prevention, epidemiology, and social and behavioural science.

While the latest scientific advances will take centre stage in Geneva, an extensive community programme has been organised to provide a forum for the exchange of information and ideas among the diverse communities affected by HIV/AIDS, and to ensure that knowledge and skills are sustained once participants return home.

"AIDS has compelled the scientific and HIV/AIDS communities to share skills, knowledge and experiences, and to forge new partnerships to fight this pandemic," said Robin Gorna, Chair of the Conference's Community Planning Committee. "It is in this spirit of collaboration that for the first time in the history of world AIDS conferences, both scientific and HIV community representatives have equal say in the format and content of the Conference programme."

– more –

Media Registration and Facilities

Daily press conferences will highlight the most important research and issues discussed at the Conference, and state-of-the-art media facilities, including phone, fax and modem connections, and closed-circuit broadcast of plenary sessions will be provided.

Credentialed journalists are encouraged to submit their completed media registration and accommodation forms early as possible, as space is limited. Credentialed requirements and media registration forms are included in the enclosed announcement. Hotel rooms reserved for the media will be assigned on a first-come, first-served basis, and accommodation requests must be submitted by April 1, 1998.

Conference Programme

Highlights of the week-long conference include:

- **Plenary Sessions:** These sessions will feature the world's most distinguished AIDS researchers, community leaders and policy specialists, and will focus on the gaps in AIDS treatment, awareness, prevention and human rights that must be closed to effectively address the epidemic in all countries.
- **Scientific Presentations:** Oral, slide and poster sessions will be presented in four tracks: A – Basic Science; B – Clinical Science and Care; C – Epidemiology, Prevention and Public Health; and D – Social and Behavioural Science. The scientific focus of tracks C and D has been strengthened. Policy implications and community perspectives will be included in all four tracks.
- **Community Sessions:** Community aspects of the programme will include skills building sessions, orientation sessions, and extensive opportunities for dialogue and exchange.

Scholarship Programme

An ambitious scholarship programme has been established to ensure that representatives from all regions most affected by HIV/AIDS are able to attend. Priority will be given to community representatives and researchers who will participate actively and contribute directly to the Conference programme. Special consideration will also be given to assist journalists from resource-poor environments to participate actively in the Conference. Scholarship application forms, provided in the attached announcement, must be submitted by February 2, 1998.

The 12th World AIDS Conference is organized by a non-profit association with a Secretariat in Geneva, under the auspices of the International AIDS Society. Conference co-organizers include The Joint United Nations Programme on HIV/AIDS, The Global Network of People Living with HIV/AIDS, The International AIDS Society, The International Council of AIDS Service Organizations, The International Community of Women Living with HIV and AIDS, and The Canton of Geneva.

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

IMPORTANT DATES 1998

► **FEBRUARY 2**

- Deadline for abstract submission
- Deadline for scholarship applications
- Deadline for early registration fee
- Deadline for cancellation of registration with full refund
- Deadline for NGO booth requests
- Deadline for Satellite Meeting requests

► **APRIL 1**

- Deadline for accommodation requests
- Deadline for cancellation of accommodation with refund less CHF 50

► **MAY 1**

- Deadline for standard registration fee
- Deadline for cancellation of registration with 50% refund
- Deadline for child care requests

► **JUNE 1**

- Deadline for "Late Breakers"

As a result of limited space, we urge interested parties to register as early as possible.

Please note that should registration be limited at any time before the Conference begins, there will be no on-site registration.

Bridging the Gap

**12th World AIDS
Conference Geneva
June 28–July 3 1998**



Second Announcement & Call for Abstracts

■


Abstract Form

Abstracts must be received no later than February 2, 1998

Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.
DO NOT FAX THIS FORM.

Courier address: Linnégatan 89 A, Stockholm, Sweden.



Abstract Option 1 ☐ Abstract Option 2 ☐

Location of research or project (country) _____ Community organisation ☐

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1:Track/Category _____ Choice 2:Track/Category _____ Serial No. _____

For Office Use Only

1

2

3

Name and full address of contact author

Name _____

Address _____

City _____

Country _____

Fax _____ E-mail _____

5 I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting. I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts.

Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐ No ☐

List of Authors and their affiliations

Presenting author (if different from contract author):

Co-authors:

Abstract Form

Abstracts must be received no later than February 2, 1998

Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.
DO NOT FAX THIS FORM.

Courier address: Linnégatan 89 A, Stockholm, Sweden.

Abstract Option 1

☐

Abstract Option 2

☐

Location of research or project (country)

Community organisation

☐

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category

Choice 2: Track/Category

For Office Use Only

Serial No.

1

2

3

Name and full address of contact author

5

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☐



12th World AIDS
Conference Geneva
June 28-July 3 1998

List of Authors and their affiliations

Presenting author (if different from contract author):

Co-authors:

Sample Abstract Form

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☒ Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

A R G E N T I N A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category A 1 4

Choice 2: Track/Category B 8

Serial No.

Early diagnosis of Tuberculosis (TB) in HIV patients by standard methods and polymerase chain reaction (PCR)

Objectives: To compare the results of the common diagnostics methods of TB (clinical preventive diagnosis, direct smear and culture) and PCR in patients with HIV infection and pulmonary infiltrates.

Design: Prospective, controlled study.

Methods: Adult patients with confirmed HIV infection and active pulmonary disease were included and a clinical preventive diagnosis was defined on admission. We exclude patients who received antimycobacterial treatment in the 9 weeks prior to admission. Pulmonary samples, blood and extrapulmonary sites specimens were processed for smear and culture of common bacteria, mycobacteria and fungi. Bold cultures were processed by lysis-centrifugation. Direct smears of pulmonary samples were stained for detection of P. carinii. Nested-PCR was performed in all samples using oligonucleotides based on the repetitive sequence IS6110, specific of M. tuberculosis complex. The gold standard for TB was defined as all positive culture for M. tuberculosis or objective response to standard anti-tuberculous treatment when no other therapy was applied.

Results: A total of 80 episodes were analyzed, 30 % (24/80) were diagnosed as TB. The sensitivity and specificity of PCR were 95, 65 % and 97,77 % respectively, as compared with the initial clinical diagnosis (82,6 % and 73,33 %), direct smear (47,8 % and 93,33 %) and culture (52,5 % and 100 %). We observed four false positive results with PCR, three in patients without clinical diagnosis of TB and one with M. kansasii.

Conclusion: PCR appeared to be an adequate method in the clinical scenario. The combination of clinical diagnosis and PCR are useful to initiate early and safe anti-tuberculous treatment in patients with HIV infection and pulmonary infiltrates.

Name and full address of contact author

L O S S O

M A R C E L O H

L A P R I D A 1 9 1 6 5

1 4 2 5 B U E N O S A I R E S

A R G E N T I N A

5 4 1 - 7 8 5 - 7 8 8 4

5 4 1 - 8 0 5 - 5 4 2 2

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts

Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☒

SAMPLE ABSTRACT FORM

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☐ Abstract Option 2 ☒

Location of research or project (country)

Community organisation ☒

I N D I A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1:Track/Category C 2 0

Choice 2:Track/Category C 4 1

Serial No.

Drug Intervention/Awareness among IDUs in the Slums

Issue: Population vulnerable to HIV/AIDS through IDU usage in the slums require innovative and appropriate intervention and awareness.

Project: Given the rapid increase in the number of IDUs in Delhi slums, an intervention using client perceptions through planning stages was developed. To this effect, a Harm Reduction programme with a Drop-In centre was established with IDUs from a socioeconomically deprived background in focus. This project includes in its staffing, rehabilitated exdrug users working as peer educators, a professionally qualified medical practitioner and a social worker. Strategies include an oral Buprenorphine maintenance programme (the only one in Asia), IDU needle/syringe exchange, one-to-one information and counselling on HIV/AIDS, a drop-in centre and sex education accompanied by distribution of condoms.

Results: The Harm Reduction Programme has been very well received by the slum dwellers. Within six months the number of clients increased from 15 to 288 exceeding our envisaged figure by over 100%. Many IDUs have stopped injecting, switching instead to safer methods of use leading to IDU prevention. A total of 789 doctor-client consultations have been recorded and 28 clients have been admitted to a full-time rehabilitation centre not including seven more who have been detoxified.

Lessons Learned: Harm reduction programmes in the slums are potentially successful if they are specifically addressed to meet the specific needs and understanding of the slum.

Name and full address of contact author

K A N G A

K E I T H

S H A R A N

T - 3 G R E E N P A R K (M A I N) N E W D E L H I

I N D I A 1 1 0 0 1 6

9 1 - 1 1 - 6 8 5 8 0 8 6

9 1 - 1 1 - 6 8 5 8 5 0 1

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting

I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts

Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☒

Registration Form

Unless specified otherwise, your name will be included in a participant list

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:

Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Courier address:

Congrex Sweden AB
Linnégatan 89A
Stockholm
Sweden

Family Name _____
Given Name _____
Company/Organisation or _____
Community Organisation _____
Street and Number _____
City and Code _____
Country _____
Telephone _____ Fax _____
E-mail _____
Accompanying Person's Name _____
Children 0–2,5 yrs ☐ 3–8 yrs ☐ Special requests _____



CHF 50 of your registration fee will cover your IAS 1998–1999 membership OR be used to support the Conference Scholarship Fund, OR to support the following three Conference co-organisers.
Please indicate your choice by ticking the appropriate box.

IAS ☐ Conference Scholarship Fund ☐ ICASO/ICW/GNP+ ☐

REFUND POLICY

- Cancellations received in writing before February 2, 1998 will be fully refunded less CHF 100, administration fee
- A 50 % refund will apply before May 1, 1998
- After May 1, 1998 no refunds

VAT No: 410

VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

REGISTRATION

Regular Delegate

	No of pers or items	Price/pers or item	CHF Swiss francs
Before February 2, 1998	1	940	_____
Before May 1, 1998	1	1065	_____
After May 1, 1998	1	1190	_____

Student (You must furnish proof of your student's status together with the registration)

Before May 1, 1998	1	590	_____
--------------------	---	-----	-------

Conference Record (Abstracts) *

Choose one version print ☐ or CD-ROM ☐	1	included	_____
I wish to have both versions ☐		50	_____

Post-conference update CD * ☐ (See explanation on page 5, under "CDs")	1	(150)	_____
---	---	-------	-------

Bag Lunches *

Monday–Tuesday–Wednesday–Thursday (4 days à CHF 11)		44	_____
---	--	----	-------

Accompanying Persons *

(Opening/Closing/Sightseeing Tour)	1	100	_____
------------------------------------	---	-----	-------

* VAT 6,5% is included

Total Registration Fees _____

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.

Please indicate which of the following means of payment you have used.

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐

Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date _____
M M Y Y

Credit Card No _____

Card Holder's Name _____

Date _____ Card Holder's Signature _____

We regret we are
unable to accept
personal, company,
or Eurocheques

Accommodation and Tour Form

(One form per participant, please)

12th World AIDS
Conference Geneva
June 28-July 3 1998



Return this form to:
AKM Travel AB
Attn: AIDS 98
Rosentalstrasse 71
CH-4016 Basel
Switzerland
Phone: +41 61 690 9411
Fax: +41 61 690 9414

no later than
April 1, 1998

Booking/change
fee of CHF 25
after April 1, 1998

Family Name _____

Given Name _____

Company/Organisation or _____

Community Organisation _____

Media Representatives, tick here ☐

Street and Number _____

City and Code _____

Country _____

Telephone _____ Fax _____

E-mail _____

Accompanying Person's Name _____

ACCOMMODATION

Date of arrival _____ Estimated time _____

Date of departure _____ Number of nights _____

Special requests _____

Please note: A minimum stay of 4 nights is required by all hotels

Arrival by car ☐ train ☐ airplane ☐

REFUND POLICY

- Cancellations received in writing before April 1, 1998 will be fully refunded less CHF 50, administration fee
- After April 1, 1998 no refunds

Reservations will be confirmed only upon receipt of your hotel deposit

Rates include service, taxes and breakfast

Category	Single room/night CHF Swiss francs	Double room/night CHF Swiss francs
A	310-355 ☐	380-435 ☐
B	270-310 ☐	320-370 ☐
C	220-260 ☐	260-310 ☐
D	170-210 ☐	200-250 ☐
E	120-160 ☐	140-190 ☐
F (Limited)	80-110 ☐	80-130 ☐

In case the category I have chosen is fully booked, please book me in the next available higher ☐ lower ☐ category

Transfer of Subtotal CHF _____

TOURS

		No. of persons	Price per person	CHF Swiss francs
Sightseeing Tour *				
Monday June 29	11.00-13.00	_____	30	_____
Tuesday June 30	09.00-11.00	_____	30	_____
Lake Cruise *				
Monday June 29	15.00-17.00	_____	35	_____
Tuesday June 30	15.00-17.00	_____	35	_____
Castle of Chillon *				
Wednesday July 1	09.00-13.30	_____	78	_____
Thursday July 2	09.00-13.30	_____	78	_____
Convent of St. Maurice *				
Wednesday July 1	09.00-18.00	_____	100	_____
Castle of Dardagny and Wine-Tasting *				
Thursday July 2	14.00-17.00	_____	50	_____
Chamonix-Mont Blanc *				
Thursday July 2	09.00-17.00	_____	95	_____
Post Conference Tour *				
Saturday July 4 – Monday July 6		_____	810	_____
Single supplement		_____	50	_____

* Vat 6.5% is included Grand Total CHF _____

Please include a copy of the banker's draft made out to AKM Travel, or a copy of your bank transfer to Union Bank of Switzerland, account No. 595.400.02H WAC or provide a credit card that we can debit. Your name and AIDS 98 should accompany all payments.

Please indicate below which of the following means of payment you have used for accommodation and tours.

Make sure to indicate AKM, AIDS 98 and your name on all money transfers.

Banker's Draft ☐

Bank Transfer (free of charge for recipient) to Union Bank of Switzerland 595.400.02H WAC ☐

Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Diners Club ☐

Credit Card No

Expiry date Card Holder's name

Date Card Holder's signature _____

We regret we are
unable to accept
personal or
company cheques

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.



Scholarship Application

Guide to Scholarship Application

The information you provide on this form is considered confidential and will only be shared with the staff and organisers of the Geneva 98 Conference for the purpose of reviewing and selecting scholarship recipients. Scholarship applicants will be told if they have been selected to receive a scholarship during the month of April 1998.

This Scholarship Programme will help to bring delegates from developing countries, educators, caregivers, health professionals, researchers, community workers and persons living with HIV/AIDS to the 12th World AIDS Conference. The total number of scholarships available is not known at this time but it will be limited. All applicants are therefore strongly advised to seek funding from other sources.

Note that persons who filled out an earlier version of this application form are asked to fill in this form. Those who filled out the previous form, however, will still be considered for a scholarship.

Scholarship Options

Not all of your expenses to attend the Conference will necessarily be paid. In some cases, however, full financial support will be considered.

Please indicate the support you really need:

- ☐ Registration fee
- ☐ Air travel (prepaid ticket at lowest fare)
- ☐ Accommodation (shared or dormitory)
- ☐ Living allowance while in Geneva

Application Procedure

Documents required:

- Completed application form
- A letter of support from your employer, your AIDS organisation, or your support group (with a contact person and telephone number) **must be attached** to your application.
- If you are submitting an abstract, please attach it to your application

APPLICANT INFORMATION (Please print or type)

Family Name

Given Name

Organisation

Your role and duties in that organisation

Mailing address

Street and Number

City and Code

Country

Telephone Fax

E-mail

Courier address (if different from mailing address)

Street and Number

City and Code

Country

Media Registration Form



12th World AIDS
Conference Geneva
June 28 – July 3 1998

Return this form to:

Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Family Name		
Given Name		
Company/Organisation		
Street and Number		
City and Code		
Country		
Telephone		Fax
E-mail		

REGISTRATION	No of pers or items	Price/pers or item	CHF Swiss francs
Media		0	0
Print ☐			
Broadcast ☐			
(credentials required)			
Conference Record (Abstracts) *			
print ☐		50	
CD-ROM ☐		50	
both ☐		100	
* VAT 6,5% is included		Total	

VAT No: 410 608
VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

We regret we are
unable to accept
personal, company,
or Eurocheques

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft	☐	Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79	☐
Visa	☐	American Express	☐
		Eurocard/Mastercard	☐
		Expiry date	
Credit Card No			
Card Holder's Name			

Date

Card Holder's Signature _____
I hereby authorise Congrex to debit this credit card account for the total amount due. I also consent to Congrex debiting or crediting my credit card account with the amount of any subsequent change(s) to the items booked.

Abstract *Receipt Acknowledgement* Card

Complete this card to receive an acknowledgement of receipt of your abstract.
Please print your full name and address on the other side so we can mail the card
back to you. Please include this card in the envelope with your Abstract Form.

This is to confirm that we have received your abstract. By April 15, 1998 you will receive
written notice as to whether your abstract has been accepted for either oral or poster
presentation at the 12th World AIDS Conference. In any future communications with
Congrex please refer to your abstract by the number assigned to it below.

Abstract Registration Number
(To be assigned by Congrex)

**PHOTOCOPY
PRESERVATION**

**12th World AIDS
Conference Geneva
June 28–July 3 1998**



Name _____

Address _____

Country _____

*Abstract Acknowledgement
sent from:*

Congrex Sweden AB
P.O. Box 5619
SE-114 86 Stockholm
Sweden

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

IMPORTANT DATES 1998

► FEBRUARY 2

- Deadline for abstract submission
- Deadline for scholarship applications
- Deadline for early registration fee
- Deadline for cancellation of registration with full refund
- Deadline for NGO booth requests
- Deadline for Satellite Meeting requests

► APRIL 1

- Deadline for accommodation requests
- Deadline for cancellation of accommodation with refund less CHF 50

► MAY 1

- Deadline for standard registration fee
- Deadline for cancellation of registration with 50% refund
- Deadline for child care requests

► JUNE 1

- Deadline for "Late Breakers"

As a result of limited space, we urge interested parties to register as early as possible. Please note that should registration be limited at any time before the Conference begins, there will be no on-site registration.

Bridging the Gap

**12th World AIDS
Conference Geneva
June 28–July 3 1998**



**+ American
Red Cross**

**HIV/AIDS
EDUCATION**

→ addressed to Patsy

I thought Sandy
might be
interested

→ JLD

Second Announcement & Call for Abstracts



Abstract Form

Abstracts must be received no later than February 2, 1998



Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.
DO NOT FAX THIS FORM.
Courier address: Linnégatan 89 A, Stockholm, Sweden.

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☐	Abstract Option 2 ☐
Location of research or project (country)	Community organisation ☐
Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)	
Choice 1: Track/Category	Choice 2: Track/Category

For Office Use Only

Serial No.

For Office Use Only



For Office Use Only



For Office Use Only



For Office Use Only

Name and full address of contact author



I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☐




■

Abstract Form

Abstracts must be received no later than February 2, 1998

Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.
DO NOT FAX THIS FORM.
Courier address: Linnégatan 89 A, Stockholm, Sweden.



Abstract Option 1 ☐	Abstract Option 2 ☐
Location of research or project (country)	Community organisation ☐
Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)	
Choice 1: Track/Category	Choice 2: Track/Category
For Office Use Only	Serial No.
1	(Abstract title)

2	Body of abstract
3	(Conclusion/Lessons Learned) (max 5 lines)

Name and full address of contact author	
Family name	
Given name	
Address	
City	
Country	
Telephone	
Fax	
E-mail	

5	I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts Presenting author's signature _____	The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award: Yes ☐ No ☐
---	--	---

List of Authors and their affiliations		
Presenting author (if different from contract author):		
Family name	Given name	
Affiliation		
City	State (if applicable)	Country

Co-authors:		
1. Family name	Initial(s)	
Affiliation		
City	State (if applicable)	Country
2. Family name	Initial(s)	
Affiliation		
City	State (if applicable)	Country
3. Family name	Initial(s)	
Affiliation		
City	State (if applicable)	Country
4. Family name	Initial(s)	
Affiliation		
City	State (if applicable)	Country
5. Family name	Initial(s)	
Affiliation		
City	State (if applicable)	Country
6. Family name	Initial(s)	
Affiliation		
City	State (if applicable)	Country

Sample Abstract Form

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☒ Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

A R G E N T I N A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category A 1 4

Choice 2: Track/Category B 8

Serial No.

Early diagnosis of Tuberculosis (TB) in HIV patients by standard methods and polymerase chain reaction (PCR)

Objectives: To compare the results of the common diagnostics methods of TB (clinical preventive diagnosis, direct smear and culture) and PCR in patients with HIV infection and pulmonary infiltrates.

Design: Prospective, controlled study.

Methods: Adult patients with confirmed HIV infection and active pulmonary disease were included and a clinical preventive diagnosis was defined on admission. We exclude patients who received antimycobacterial treatment in the 9 weeks prior to admission. Pulmonary samples, blood and extrapulmonary sites specimens were processed for smear and culture of common bacteria, mycobacteria and fungi. Bold cultures were processed by lysis-centrifugation. Direct smears of pulmonary samples were stained for detection of P.carinii. Nested-PCR was performed in all samples using oligonucleotides based on the repetitive sequence IS6110, specific of M.tuberculosis complex. The gold standard for TB was defined as all positive culture for M.tuberculosis or objective response to standard anti-tuberculous treatment when no other therapy was applied.

Results: A total of 80 episodes were analyzed, 30 % (24/80) were diagnosed as TB. The sensitivity and specificity of PCR were 95, 65 % and 97,77 % respectively, as compared with the initial clinical diagnosis (82,6 % and 73,33 %), direct smear (47,8 % and 93,33 %) and culture (52,5 % and 100 %). We observed four false positive results with PCR, three in patients without clinical diagnosis of TB and one with M.kansaii.

Conclusion: PCR appeared to be an adequate method in the clinical scenario. The combination of clinical diagnosis and PCR are useful to initiate early and safe anti-tuberculous treatment in patients with HIV infection and pulmonary infiltrates.

Name and full address of contact author

L O S S O

M A R C E L O H

L A P R I D A 1 9 1 6 5

1 4 2 5 B U E N O S A I R E S

A R G E N T I N A

5 4 1 - 7 8 5 - 7 8 8 4

5 4 1 - 8 0 5 - 5 4 2 2

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts

Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☒

SAMPLE ABSTRACT FORM

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☐ Abstract Option 2 ☒

Location of research or project (country)

Community organisation ☒

I N D I A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1:Track/Category C 2 0

Choice 2:Track/Category C 4 1

Serial No.

Drug Intervention/Awareness among IDUs in the Slums

Issue: Population vulnerable to HIV/AIDS through IDU usage in the slums require innovative and appropriate intervention and awareness.

Project: Given the rapid increase in the number of IDUs in Delhi slums, an intervention using client perceptions through planning stages was developed. To this effect, a Harm Reduction programme with a Drop-In centre was established with IDUs from a socioeconomically deprived background in focus. This project includes in its staffing, rehabilitated exdrug users working as peer educators, a professionally qualified medical practitioner and a social worker. Strategies include an oral Buprenorphine maintenance programme (the only one in Asia), IDU needle/syringe exchange, one-to-one information and counselling on HIV/AIDS, a drop-in centre and sex education accompanied by distribution of condoms.

Results: The Harm Reduction Programme has been very well received by the slum dwellers. Within six months the number of clients increased from 15 to 288 exceeding our envisaged figure by over 100%. Many IDUs have stopped injecting, switching instead to safer methods of use leading to IDU prevention. A total of 789 doctor-client consultations have been recorded and 28 clients have been admitted to a full-time rehabilitation centre not including seven more who have been detoxified.

Lessons Learned: Harm reduction programmes in the slums are potentially successful if they are specifically addressed to meet the specific needs and understanding of the slum.

Name and full address of contact author

K A N G A

K E I T H

S H A R A N

T - 3 G R E E N P A R K (M A I N) N E W D E L H I

I N D I A 1 1 0 0 1 6

9 1 - 1 1 - 6 8 5 8 0 8 6

9 1 - 1 1 - 6 8 5 8 5 0 1

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐ No ☒

Registration Form

Unless specified otherwise, your name will be included in a participant list

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:
Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Courier address:
Congrex Sweden AB
Linnégatan 89A
Stockholm
Sweden

Family Name _____
Given Name _____
Company/Organisation or _____
Community Organisation _____
Street and Number _____
City and Code _____
Country _____
Telephone _____ Fax _____
E-mail _____
Accompanying Person's Name _____
Children 0–2,5 yrs ☐ 3–8 yrs ☐ Special requests _____



CHF 50 of your registration fee will cover your IAS 1998–1999 membership OR be used to support the Conference Scholarship Fund, OR to support the following three Conference co-organisers.
Please indicate your choice by ticking the appropriate box.

IAS ☐ Conference Scholarship Fund ☐ ICASO/ICW/GNP+ ☐

REFUND POLICY

- Cancellations received in writing before February 2, 1998 will be fully refunded less CHF 100, administration fee
- A 50 % refund will apply before May 1, 1998
- After May 1, 1998 no refunds

VAT No: 410

VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

REGISTRATION

Regular Delegate

Before February 2, 1998	1	940	_____
Before May 1, 1998	1	1065	_____
After May 1, 1998	1	1190	_____

Student (You must furnish proof of your student's status together with the registration)

Before May 1, 1998	1	590	_____
--------------------	---	-----	-------

Conference Record (Abstracts) *

Choose one version print ☐ or CD-ROM ☐	1	included	_____
I wish to have both versions ☐		50	_____

Post-conference update CD * ☐ (See explanation on page 5, under "CDs")	1	(150)	_____
---	---	-------	-------

Bag Lunches *

Monday–Tuesday–Wednesday–Thursday (4 days à CHF 11)		44	_____
---	--	----	-------

Accompanying Persons *

(Opening/Closing/Sightseeing Tour)	1	100	_____
------------------------------------	---	-----	-------

* VAT 6,5% is included

Total Registration Fees _____

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐

Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date _____

Credit Card No _____

Card Holder's Name _____

Date _____ Card Holder's Signature _____

We regret we are
unable to accept
personal, company,
or Eurocheques

Accommodation and Tour Form

(One form per participant, please)

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:
AKM Travel AB
Attn: AIDS 98
Rosentalstrasse 71
CH-4016 Basel
Switzerland
Phone: +41 61 690 9411
Fax: +41 61 690 9414

no later than
April 1, 1998

Booking/change
fee of CHF 25
after April 1, 1998

Family Name _____

Given Name _____

Company/Organisation or _____

Community Organisation _____

Media Representatives, tick here ☐

Street and Number _____

City and Code _____

Country _____

Telephone _____ Fax _____

E-mail _____

Accompanying Person's Name _____

ACCOMMODATION

Date of arrival _____ Estimated time _____

Date of departure _____ Number of nights _____

Special requests _____

Please note: A minimum stay of 4 nights is required by all hotels

Arrival by car ☐ train ☐ airplane ☐

REFUND POLICY

- Cancellations received in writing before April 1, 1998 will be fully refunded less CHF 50, administration fee
- After April 1, 1998 no refunds

Reservations will be confirmed only upon receipt of your hotel deposit

Rates include service, taxes and breakfast

Category	Single room/night CHF Swiss francs	Double room/night CHF Swiss francs
A	310–355 ☐	380–435 ☐
B	270–310 ☐	320–370 ☐
C	220–260 ☐	260–310 ☐
D	170–210 ☐	200–250 ☐
E	120–160 ☐	140–190 ☐
F (Limited)	80–110 ☐	80–130 ☐

In case the category I have chosen is fully booked, please book me in the next available higher ☐ lower ☐ category

Transfer of Subtotal CHF _____

TOURS

		No. of persons	Price per person	CHF Swiss francs
Sightseeing Tour *				
Monday June 29	11.00-13.00	_____	30	_____
Tuesday June 30	09.00-11.00	_____	30	_____
Lake Cruise *				
Monday June 29	15.00-17.00	_____	35	_____
Tuesday June 30	15.00-17.00	_____	35	_____
Castle of Chillon *				
Wednesday July 1	09.00-13.30	_____	78	_____
Thursday July 2	09.00-13.30	_____	78	_____
Convent of St. Maurice *				
Wednesday July 1	09.00-18.00	_____	100	_____
Castle of Dardagny and Wine-Tasting *				
Thursday July 2	14.00-17.00	_____	50	_____
Chamonix-Mont Blanc *				
Thursday July 2	09.00-17.00	_____	95	_____
Post Conference Tour *				
Saturday July 4 – Monday July 6		_____	810	_____
Single supplement		_____	50	_____

* Vat 6.5% is included Grand Total CHF _____

Please include a copy of the banker's draft made out to AKM Travel, or a copy of your bank transfer to Union Bank of Switzerland, account No. 595.400.02H WAC or provide a credit card that we can debit. Your name and AIDS 98 should accompany all payments.
Please indicate below which of the following means of payment you have used for accommodation and tours.

Make sure to indicate AKM, AIDS 98 and your name on all money transfers.

- Banker's Draft ☐
- Bank Transfer (free of charge for recipient) to Union Bank of Switzerland 595.400.02H WAC ☐
- Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Diners Club ☐

Credit Card No _____

Expiry date

_____	_____	_____	_____
M	M	Y	Y

 Card Holder's name _____

Date

_____	_____	_____	_____	_____	_____
D	D	M	M	Y	Y

 Card Holder's signatue _____

We regret we are
unable to accept
personal or
company cheques

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.



12th World AIDS
Conference Geneva
June 28 – July 3 1998

Scholarship Application

Guide to Scholarship Application

The information you provide on this form is considered confidential and will only be shared with the staff and organisers of the Geneva 98 Conference for the purpose of reviewing and selecting scholarship recipients. Scholarship applicants will be told if they have been selected to receive a scholarship during the month of April 1998.

This Scholarship Programme will help to bring delegates from developing countries, educators, caregivers, health professionals, researchers, community workers and persons living with HIV/AIDS to the 12th World AIDS Conference. The total number of scholarships available is not known at this time but it will be limited. All applicants are therefore strongly advised to seek funding from other sources.

Note that persons who filled out an earlier version of this application form are asked to fill in this form. Those who filled out the previous form, however, will still be considered for a scholarship.

Scholarship Options

Not all of your expenses to attend the Conference will necessarily be paid. In some cases, however, full financial support will be considered.

Please indicate the support you really need:

- ☐ Registration fee
- ☐ Air travel (prepaid ticket at lowest fare)
- ☐ Accommodation (shared or dormitory)
- ☐ Living allowance while in Geneva

Application Procedure

Documents required:

- Completed application form
- A letter of support from your employer, your AIDS organisation, or your support group (with a contact person and telephone number) **must be attached** to your application.
- If you are submitting an abstract, please attach it to your application

APPLICANT INFORMATION (Please print or type)

Family Name

Given Name

Organisation

Your role and duties in that organisation

Mailing address

Street and Number

City and Code

Country

Telephone Fax

E-mail

Courier address (if different from mailing address)

Street and Number

City and Code

Country

Media Registration Form

12th World AIDS
Conference Geneva
June 28-July 3 1998



Return this form to:
Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Family Name _____
Given Name _____
Company/Organisation _____
Street and Number _____
City and Code _____
Country _____
Telephone _____ Fax _____
E-mail _____

REGISTRATION	No of pers or items	Price/pers or item	CHF Swiss francs
Media		0	0
Print ☐			
Broadcast ☐			
(credentials required)			
Conference Record (Abstracts) *			
print ☐		50	
CD-ROM ☐		50	
both ☐		100	
* VAT 6,5% is included		Total	

VAT No: 410 608
VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

We regret we are
unable to accept
personal, company,
or Eurocheques

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐
Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date _____
Credit Card No _____
Card Holder's Name _____

Date _____
D D M M Y Y

Card Holder's Signature _____
I hereby authorise Congrex to debit this credit card account for the total amount due. I also consent to Congrex debiting or crediting my credit card account with the amount of any subsequent change(s) to the items booked.

Abstract **Receipt Acknowledgement** Card

Complete this card to receive an acknowledgement of receipt of your abstract.
Please print your full name and address on the other side so we can mail the card
back to you. Please include this card in the envelope with your Abstract Form.

This is to confirm that we have received your abstract. By April 15, 1998 you will receive
written notice as to whether your abstract has been accepted for either oral or poster
presentation at the 12th World AIDS Conference. In any future communications with
Congrex please refer to your abstract by the number assigned to it below.

Abstract Registration Number
(To be assigned by Congrex)

**PHOTOCOPY
PRESERVATION**

**12th World AIDS
Conference Geneva
June 28–July 3 1998**



Name _____

Address _____

Country _____

*Abstract Acknowledgement
sent from:*

Congrex Sweden AB
P.O. Box 5619
SE-114 86 Stockholm
Sweden

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

IMPORTANT DATES 1998

► FEBRUARY 2

- Deadline for abstract submission
- Deadline for scholarship applications
- Deadline for early registration fee
- Deadline for cancellation of registration with full refund
- Deadline for NGO booth requests
- Deadline for Satellite Meeting requests

► APRIL 1

- Deadline for accommodation requests
- Deadline for cancellation of accommodation with refund less CHF 50

► MAY 1

- Deadline for standard registration fee
- Deadline for cancellation of registration with 50% refund
- Deadline for child care requests

► JUNE 1

- Deadline for "Late Breakers"

As a result of limited space, we urge interested parties to register as early as possible.

Please note that should registration be limited at any time before the Conference begins, there will be no on-site registration.

Bridging the Gap

**12th World AIDS
Conference Geneva
June 28–July 3 1998**



Second Announcement & Call for Abstracts

Abstract Form

Abstracts must be received no later than February 2, 1998

Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.

DO NOT FAX THIS FORM.

Courier address: Linnégatan 89 A, Stockholm, Sweden.

12th World AIDS
Conference Geneva
June 28–July 3 1998



Abstract Option 1 ☐ Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category

Choice 2: Track/Category

Serial No.

For Office Use Only

1

Abstract title

2

Body of abstract

3

Concise summary of the abstract
maximum 100 words

Name and full address of contact author

5

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting. I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts.
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☐

List of Authors and their affiliations

Presenting author (if different from contract author):

Family name:

Publication:

Co-authors:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

Family name:

Publication:

■

Abstract Form

Abstracts must be received no later than February 2, 1998

Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.
DO NOT FAX THIS FORM.
Courier address: Linnégatan 89 A, Stockholm, Sweden.



12th World AIDS
Conference Geneva
June 28–July 3 1998

Abstract Option 1 ☐

Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category

Choice 2: Track/Category

For Office Use Only

Serial No.

For editorial use only

Abstract number

2

(Body of abstract)

3

(Conclusion/Lessons learned)
(max 5 lines)

Name and full address of contact author

Email address

Telephone

Country

Postcode

E-mail

5

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☐

Presenting author (if different from contract author):

Given name

‘*Stigite vāi anq’elē-šānē*’)

Conclusions

internally, and

| initial(s) | |

3.4.4. *Other types of models*

CONCLUSIONS

$$\text{Ind}(\text{Ind}(s))$$

Publicly available data

CONCLUSIONS

$$\text{Initial}(z)$$

State (if applicable)

(continue)

initial(s)

State (if applying alone)

Country.

initial(s) =

Future (development)

6. **Данное**

Source (ii) is applicable)

Country

Sample Abstract Form

12th World AIDS
Conference Geneva
June 28 – July 3 1998

Abstract Option 1 ☒ Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

A R G E N T I N A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category A 1 4

Choice 2: Track/Category B 8

Serial No.

Early diagnosis of Tuberculosis (TB) in HIV patients by standard methods and polymerase chain reaction (PCR)

Objectives: To compare the results of the common diagnostics methods of TB (clinical preventive diagnosis, direct smear and culture) and PCR in patients with HIV infection and pulmonary infiltrates.

Design: Prospective, controlled study.

Methods: Adult patients with confirmed HIV infection and active pulmonary disease were included and a clinical preventive diagnosis was defined on admission. We exclude patients who received antimycobacterial treatment in the 9 weeks prior to admission. Pulmonary samples, blood and extrapulmonary sites specimens were processed for smear and culture of common bacteria, mycobacteria and fungi. Bold cultures were processed by lysis-centrifugation. Direct smears of pulmonary samples were stained for detection of P.carinii. Nested-PCR was performed in all samples using oligonucleotides based on the repetitive sequence IS6110, specific of M.tuberculosis complex. The gold standard for TB was defined as all positive culture for M.tuberculosis or objective response to standard anti-tuberculous treatment when no other therapy was applied.

Results: A total of 80 episodes were analyzed, 30 % (24/80) were diagnosed as TB. The sensitivity and specificity of PCR were 95, 65 % and 97,77 % respectively, as compared with the initial clinical diagnosis (82,6 % and 73,33 %), direct smear (47,8 % and 93,33 %) and culture (52,5 % and 100 %). We observed four false positive results with PCR, three in patients without clinical diagnosis of TB and one with M.kansaii.

Conclusion: PCR appeared to be an adequate method in the clinical scenario. The combination of clinical diagnosis and PCR are useful to initiate early and safe anti-tuberculous treatment in patients with HIV infection and pulmonary infiltrates.

Name and full address of contact author

L O S S O

M A R C E L O H

L A P R I D A 1 9 1 6 5

1 4 2 5 B U E N O S A I R E S

A R G E N T I N A

5 4 1 - 7 8 5 - 7 8 8 4

5 4 1 - 8 0 5 - 5 4 2 2

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☒

SAMPLE ABSTRACT FORM

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☐ Abstract Option 2 ☒

Location of research or project (country)

Community organisation ☒

I N D I A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1:Track/Category C 2 0

Choice 2:Track/Category C 4 1

Serial No.

Drug Intervention/Awareness among IDUs in the Slums

Issue: Population vulnerable to HIV/AIDS through IDU usage in the slums require innovative and appropriate intervention and awareness.

Project: Given the rapid increase in the number of IDUs in Delhi slums, an intervention using client perceptions through planning stages was developed. To this effect, a Harm Reduction programme with a Drop-In centre was established with IDUs from a socioeconomically deprived background in focus. This project includes in its staffing, rehabilitated exdrug users working as peer educators, a professionally qualified medical practitioner and a social worker. Strategies include an oral Buprenorphine maintenance programme (the only one in Asia), IDU needle/syringe exchange, one-to-one information and counselling on HIV/AIDS, a drop-in centre and sex education accompanied by distribution of condoms.

Results: The Harm Reduction Programme has been very well received by the slum dwellers. Within six months the number of clients increased from 15 to 288 exceeding our envisaged figure by over 100%. Many IDUs have stopped injecting, switching instead to safer methods of use leading to IDU prevention. A total of 789 doctor-client consultations have been recorded and 28 clients have been admitted to a full-time rehabilitation centre not including seven more who have been detoxified.

Lessons Learned: Harm reduction programmes in the slums are potentially successful if they are specifically addressed to meet the specific needs and understanding of the slum.

Name and full address of contact author

K A N G A

K E I T H

S H A R A N

T - 3 G R E E N P A R K (M A I N) N E W D E L H I

I N D I A 1 1 0 0 1 6

9 1 - 1 1 - 6 8 5 8 0 8 6

9 1 - 1 1 - 6 8 5 8 5 0 1

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐ No ☒

Registration Form

Unless specified otherwise, your name will be included in a participant list

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:

Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Courier address:

Congrex Sweden AB
Linnégatan 89A
Stockholm
Sweden

Family Name _____
Given Name _____
Company/Organisation or _____
Community Organisation _____
Street and Number _____
City and Code _____
Country _____
Telephone _____ Fax _____
E-mail _____
Accompanying Person's Name _____
Children 0–2,5 yrs ☐ 3–8 yrs ☐ Special requests _____



CHF 50 of your registration fee will cover your IAS 1998–1999 membership OR be used to support the Conference Scholarship Fund, OR to support the following three Conference co-organisers. Please indicate your choice by ticking the appropriate box.

IAS ☐ Conference Scholarship Fund ☐ ICASO/ICW/GNP+ ☐

REFUND POLICY

- Cancellations received in writing before February 2, 1998 will be fully refunded less CHF 100, administration fee
- A 50 % refund will apply before May 1, 1998
- After May 1, 1998 no refunds

VAT No: 410

VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

REGISTRATION

Regular Delegate

	No of pers or items	Price/pers or item	CHF Swiss francs
Before February 2, 1998	1	940	_____
Before May 1, 1998	1	1065	_____
After May 1, 1998	1	1190	_____

Student (You must furnish proof of your student's status together with the registration)

Before May 1, 1998	1	590	_____
--------------------	---	-----	-------

Conference Record (Abstracts) *

Choose one version print ☐ or CD-ROM ☐	1	included	_____
I wish to have both versions ☐		50	_____
Post-conference update CD * ☐ (See explanation on page 5, under "CDs")	1	(150)	_____

Bag Lunches *

Monday–Tuesday–Wednesday–Thursday (4 days à CHF 11)		44	_____
---	--	----	-------

Accompanying Persons *

(Opening/Closing/Sightseeing Tour)	1	100	_____
------------------------------------	---	-----	-------

* VAT 6,5% is included

Total Registration Fees _____

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐

Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date

_____	_____	_____	_____
M	M	Y	Y

Credit Card No _____

Card Holder's Name _____

Date _____ Card Holder's Signature _____

We regret we are
unable to accept
personal, company,
or Eurocheques

Accommodation and Tour Form

(One form per participant, please)

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:
AKM Travel AB
Attn: AIDS 98
Rosentalstrasse 71
CH-4016 Basel
Switzerland
Phone: +41 61 690 9411
Fax: +41 61 690 9414

no later than
April 1, 1998

Booking/change
fee of CHF 25
after April 1, 1998

Family Name _____

Given Name _____

Company/Organisation or _____

Community Organisation _____

Media Representatives, tick here ☐

Street and Number _____

City and Code _____

Country _____

Telephone _____ Fax _____

E-mail _____

Accompanying Person's Name _____

ACCOMMODATION

Date of arrival _____ Estimated time _____

Date of departure _____ Number of nights _____

Special requests _____

Please note: A minimum stay of 4 nights is required by all hotels

Arrival by car ☐ train ☐ airplane ☐

REFUND POLICY

- Cancellations received in writing before April 1, 1998 will be fully refunded less CHF 50, administration fee
- After April 1, 1998 no refunds

Rates include service, taxes and breakfast

Category	Single room/night CHF Swiss francs	Double room/night CHF Swiss francs
A	310–355 ☐	380–435 ☐
B	270–310 ☐	320–370 ☐
C	220–260 ☐	260–310 ☐
D	170–210 ☐	200–250 ☐
E	120–160 ☐	140–190 ☐
F (Limited)	80–110 ☐	80–130 ☐

Reservations will be confirmed only upon receipt of your hotel deposit

In case the category I have chosen is fully booked, please book me in the next available higher ☐ lower ☐ category

Transfer of Subtotal CHF _____

TOURS

No. of persons	Price per person	CHF Swiss francs
-------------------	---------------------	---------------------

Sightseeing Tour *

Monday June 29	11.00-13.00	_____	30	_____
----------------	-------------	-------	----	-------

Tuesday June 30	09.00-11.00	_____	30	_____
-----------------	-------------	-------	----	-------

Lake Cruise *

Monday June 29	15.00-17.00	_____	35	_____
----------------	-------------	-------	----	-------

Tuesday June 30	15.00-17.00	35
-----------------	-------------	----

Castle of Chillon *

Wednesday July 1	09.00-13.30	_____	78	_____
------------------	-------------	-------	----	-------

Thursday July 2	09.00-13.30	78
-----------------	-------------	----

Convent of St. Maurice *

Wednesday July 1	09.00-18.00	<u> </u>	100	<u> </u>
------------------	-------------	-------------------	-----	-------------------

Castle of Dardagny and Wine-Tasting *

Thursday July 2	14.00-17.00	50
-----------------	-------------	----

Chamonix-Mont Blanc *

Thursday July 2	09.00-17.00		95	
-----------------	-------------	--	----	--

Post Conference Tour *

Saturday July 4 – Monday July 6 _____ 810 _____

Single supplement _____ 50 _____

*** Vat 6.5% is included**

Grand Total CHF _____

**We regret we are
unable to accept
personal or
company cheques**

Please include a copy of the banker's draft made out to AKM Travel, or a copy of your bank transfer to Union Bank of Switzerland, account No. 595.400.02H WAC or provide a credit card that we can debit. Your name and AIDS 98 should accompany all payments.

Please indicate below which of the following means of payment you have used for accommodation and tours.

Make sure to indicate AKM, AIDS 98 and your name on all money transfers.

Banker's Draft ☐

Bank Transfer (free of charge for recipient) to Union Bank of Switzerland 595.400.02H WAC ☐

Visa ☐
 American Express ☐
 Eurocard/Mastercard ☐
 Diners Club ☐

Credit Card No

[illegible]

Date

D	M	M	Y	Y	

 Card Holder's signature _____

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.



12th World AIDS
Conference Geneva
June 28–July 3 1998

Scholarship Application

Guide to Scholarship Application

The information you provide on this form is considered confidential and will only be shared with the staff and organisers of the Geneva 98 Conference for the purpose of reviewing and selecting scholarship recipients. Scholarship applicants will be told if they have been selected to receive a scholarship during the month of April 1998.

This Scholarship Programme will help to bring delegates from developing countries, educators, caregivers, health professionals, researchers, community workers and persons living with HIV/AIDS to the 12th World AIDS Conference. The total number of scholarships available is not known at this time but it will be limited. All applicants are therefore strongly advised to seek funding from other sources.

Note that persons who filled out an earlier version of this application form are asked to fill in this form. Those who filled out the previous form, however, will still be considered for a scholarship.

Scholarship Options

Not all of your expenses to attend the Conference will necessarily be paid. In some cases, however, full financial support will be considered.

Please indicate the support you really need:

- ☐ Registration fee
- ☐ Air travel (prepaid ticket at lowest fare)
- ☐ Accommodation (shared or dormitory)
- ☐ Living allowance while in Geneva

Application Procedure

Documents required:

- Completed application form
- A letter of support from your employer, your AIDS organisation, or your support group (with a contact person and telephone number) **must be attached** to your application.
- If you are submitting an abstract, please attach it to your application

APPLICANT INFORMATION (Please print or type)

Family Name

Given Name

Organisation

Your role and duties in that organisation

Mailing address

Street and Number

City and Code

Country

Telephone Fax

E-mail

Courier address (if different from mailing address)

Street and Number

City and Code

Country

Media Registration Form

12th World AIDS
Conference Geneva
June 28 – July 3 1998



Return this form to:

Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Family Name _____
Given Name _____
Company/Organisation _____
Street and Number _____
City and Code _____
Country _____
Telephone _____ Fax _____
E-mail _____

REGISTRATION

	No of pers or items	Price/pers or item	CHF Swiss francs
Media		0	0
Print ☐			
Broadcast ☐			
(credentials required)			
Conference Record (Abstracts) *			
print ☐		50	
CD-ROM ☐		50	
both ☐		100	
* VAT 6,5% is included		Total	

VAT No: 410 608
VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

We regret we are
unable to accept
personal, company,
or Eurocheques

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐
Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date _____
Credit Card No _____
Card Holder's Name _____

Date _____
D D M M Y Y

Card Holder's Signature _____
I hereby authorise Congrex to debit this credit card account for the total amount due. I also consent to Congrex debiting or crediting my credit card account with the amount of any subsequent change(s) to the items booked.

Abstract ***Receipt Acknowledgement*** Card

Complete this card to receive an acknowledgement of receipt of your abstract.
Please print your full name and address on the other side so we can mail the card
back to you. Please include this card in the envelope with your Abstract Form.

This is to confirm that we have received your abstract. By April 15, 1998 you will receive
written notice as to whether your abstract has been accepted for either oral or poster
presentation at the 12th World AIDS Conference. In any future communications with
Congrex please refer to your abstract by the number assigned to it below.

Abstract Registration Number
(To be assigned by Congrex)

**PHOTOCOPY
PRESERVATION**

**12th World AIDS
Conference Geneva
June 28-July 3 1998**



Name _____

Address _____

Country _____

*Abstract Acknowledgement
sent from:*

Congrex Sweden AB
P.O. Box 5619
SE-114 86 Stockholm
Sweden

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

IMPORTANT DATES 1998

► FEBRUARY 2

- Deadline for abstract submission
- Deadline for scholarship applications
- Deadline for early registration fee
- Deadline for cancellation of registration with full refund
- Deadline for NGO booth requests
- Deadline for Satellite Meeting requests

► APRIL 1

- Deadline for accommodation requests
- Deadline for cancellation of accommodation with refund less CHF 50

► MAY 1

- Deadline for standard registration fee
- Deadline for cancellation of registration with 50% refund
- Deadline for child care requests

► JUNE 1

- Deadline for "Late Breakers"

As a result of limited space, we urge interested parties to register as early as possible. Please note that should registration be limited at any time before the Conference begins, there will be no on-site registration.

Bridging the Gap

**12th World AIDS
Conference Geneva
June 28–July 3 1998**



Second Announcement & Call for Abstracts

Abstract Form

Abstracts must be received no later than February 2, 1998

Abstracts must be submitted on this form

Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.

DO NOT FAX THIS FORM.

Courier address: Linnégatan 89 A, Stockholm, Sweden.

12th World AIDS
Conference Geneva
June 28–July 3 1998



Abstract Option 1 ☐ Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category

Choice 2: Track/Category

For Office Use Only

Serial No.

For Office Use Only

1

Indicate track.

2

Indicate category.

3

Conditional acceptance
and review

Name and full address of contact author

5

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting. I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts.
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐

No ☐

Abstract Form

Abstracts must be received no later than February 2, 1998



Abstracts must be submitted on this form
Mail the abstracts to Congrex Sweden AB, Attn: AIDS 98, P.O. Box 5619, SE-114 86, Stockholm, Sweden.
DO NOT FAX THIS FORM.
Courier address: Linnégatan 89 A, Stockholm, Sweden.

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1: ☐ Abstract Option 2: ☐
Location of research or project (country): _____ Community organisation: ☐

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category _____ Choice 2: Track/Category _____

For Office Use Only

Serial No. _____

For Office Use Only: 1. Abstract title

2. Body of abstract

3. Conclusion (maximum 5 lines)

Name and full address of contact author

Family name _____

Given name _____

Address _____

City _____

Country _____

Telephone _____

Fax _____

E-mail _____

Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐ No ☐

List of Authors and their affiliations
Presenting author (if different from contract author):

Family name	Given name
Affiliation	
City	State (if applicable) Country

Co-authors:

1. Family name	Initial(s)
Affiliation	
City	State (if applicable) Country

2. Family name	Initial(s)
Affiliation	
City	State (if applicable) Country

3. Family name	Initial(s)
Affiliation	
City	State (if applicable) Country

4. Family name	Initial(s)
Affiliation	
City	State (if applicable) Country

5. Family name	Initial(s)
Affiliation	
City	State (if applicable) Country

6. Family name	Initial(s)
Affiliation	
City	State (if applicable) Country

Sample Abstract Form

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☒ Abstract Option 2 ☐

Location of research or project (country)

Community organisation ☐

A R G E N T I N A

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1: Track/Category A 1 4

Choice 2: Track/Category B 8

Serial No.

Early diagnosis of Tuberculosis (TB) in HIV patients by standard methods and polymerase chain reaction (PCR)

Objectives: To compare the results of the common diagnostics methods of TB (clinical preventive diagnosis, direct smear and culture) and PCR in patients with HIV infection and pulmonary infiltrates.

Design: Prospective, controlled study.

Methods: Adult patients with confirmed HIV infection and active pulmonary disease were included and a clinical preventive diagnosis was defined on admission. We exclude patients who received antimycobacterial treatment in the 9 weeks prior to admission. Pulmonary samples, blood and extrapulmonary sites specimens were processed for smear and culture of common bacteria, mycobacteria and fungi. Bold cultures were processed by lysis-centrifugation. Direct smears of pulmonary samples were stained for detection of P.carinii. Nested-PCR was performed in all samples using oligonucleotides based on the repetitive sequence IS6110, specific of M.tuberculosis complex. The gold standard for TB was defined as all positive culture for M.tuberculosis or objective response to standard anti-tuberculous treatment when no other therapy was applied.

Results: A total of 80 episodes were analyzed, 30 % (24/80) were diagnosed as TB. The sensitivity and specificity of PCR were 95, 65 % and 97,77 % respectively, as compared with the initial clinical diagnosis (82,6 % and 73,33 %), direct smear (47,8 % and 93,33 %) and culture (52,5 % and 100 %). We observed four false positive results with PCR, three in patients without clinical diagnosis of TB and one with M.kansaii.

Conclusion: PCR appeared to be an adequate method in the clinical scenario. The combination of clinical diagnosis and PCR are useful to initiate early and safe anti-tuberculous treatment in patients with HIV infection and pulmonary infiltrates.

Name and full address of contact author

L O S S O

M A R C E L O H

L A P R I D A 1 9 1 6 5

1 4 2 5 B U E N O S A I R E S

A R G E N T I N A

5 4 1 - 7 8 5 - 7 8 8 4

5 4 1 - 8 0 5 - 5 4 2 2

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:

Yes ☐ No ☒

Sample Abstract Form

12th World AIDS
Conference Geneva
June 28-July 3 1998

Abstract Option 1 ☐ Abstract Option 2 ☒

Location of research or project (country) Community organisation ☒

INDIA

For Office Use Only

Track Categories: Indicate two choices for track/category codes (e.g. A5, D12)

Choice 1:Track/Category C 2 0

Choice 2:Track/Category C 4 1

Serial No.

Drug Intervention/Awareness among IDUs in the Slums

Issue: Population vulnerable to HIV/AIDS through IDU usage in the slums require innovative and appropriate intervention and awareness.

Project: Given the rapid increase in the number of IDUs in Delhi slums, an intervention using client perceptions through planning stages was developed. To this effect, a Harm Reduction programme with a Drop-In centre was established with IDUs from a socioeconomically deprived background in focus. This project includes in its staffing, rehabilitated exdrug users working as peer educators, a professionally qualified medical practitioner and a social worker. Strategies include an oral Buprenorphine maintenance programme (the only one in Asia), IDU needle/syringe exchange, one-to-one information and counselling on HIV/AIDS, a drop-in centre and sex education accompanied by distribution of condoms.

Results: The Harm Reduction Programme has been very well received by the slum dwellers. Within six months the number of clients increased from 15 to 288 exceeding our envisaged figure by over 100%. Many IDUs have stopped injecting, switching instead to safer methods of use leading to IDU prevention. A total of 789 doctor-client consultations have been recorded and 28 clients have been admitted to a full-time rehabilitation centre not including seven more who have been detoxified.

Lessons Learned: Harm reduction programmes in the slums are potentially successful if they are specifically addressed to meet the specific needs and understanding of the slum.

Name and full address of contact author

KANGA

KEITH

SHARAN

T - 3 GREEN PARK (MAIN) NEW DELHI

INDIA 110016

91 - 11 - 6858086

91 - 11 - 6858501

I certify that this abstract has not been published elsewhere or submitted for presentation at another national or international meeting
I certify that I am complying to the Rule of Two in submitting a maximum of two abstracts
Presenting author's signature _____

The presenting author will be 35 years of age or less on February 2, 1998 and wishes to be considered for a Young Investigator Award:
Yes ☐ No ☒

Registration Form

Unless specified otherwise, your name will be included in a participant list

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:

Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Courier address:

Congrex Sweden AB
Linnégatan 89A
Stockholm
Sweden

Family Name _____
Given Name _____
Company/Organisation or _____
Community Organisation _____
Street and Number _____
City and Code _____
Country _____
Telephone _____ Fax _____
E-mail _____
Accompanying Person's Name _____
Children 0–2,5 yrs ☐ 3–8 yrs ☐ Special requests _____



CHF 50 of your registration fee will cover your IAS 1998–1999 membership OR be used to support the Conference Scholarship Fund, OR to support the following three Conference co-organisers.
Please indicate your choice by ticking the appropriate box.

IAS ☐ Conference Scholarship Fund ☐ ICASO/ICW/GNP+ ☐

REFUND POLICY

- Cancellations received in writing before February 2, 1998 will be fully refunded less CHF 100, administration fee
- A 50 % refund will apply before May 1, 1998
- After May 1, 1998 no refunds

VAT No: 410

VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
PAdr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

REGISTRATION

Regular Delegate

	No of pers or items	Price/pers or item	CHF Swiss francs
Before February 2, 1998	1	940	_____
Before May 1, 1998	1	1065	_____
After May 1, 1998	1	1190	_____

Student (You must furnish proof of your student's status together with the registration)

Before May 1, 1998	1	590	_____
--------------------	---	-----	-------

Conference Record (Abstracts) *

Choose one version print ☐ or CD-ROM ☐	1	included	_____
I wish to have both versions ☐		50	_____

Post-conference update CD * ☐ (See explanation on page 5, under "CDs")	1	(150)	_____
---	---	-------	-------

Bag Lunches *

Monday–Tuesday–Wednesday–Thursday (4 days à CHF 11)		44	_____
---	--	----	-------

Accompanying Persons *

(Opening/Closing/Sightseeing Tour)	1	100	_____
------------------------------------	---	-----	-------

* VAT 6,5% is included

Total Registration Fees _____

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐

Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date _____
M M Y Y

Credit Card No _____

Card Holder's Name _____

Date _____ Card Holder's Signature _____

We regret we are
unable to accept
personal, company,
or Eurocheques

Accommodation and Tour Form

(One form per participant, please)

12th World AIDS
Conference Geneva
June 28–July 3 1998



Return this form to:
AKM Travel AB
Attn: AIDS 98
Rosentalstrasse 71
CH-4016 Basel
Switzerland
Phone: +41 61 690 9411
Fax: +41 61 690 9414

no later than
April 1, 1998

Booking/change
fee of CHF 25
after April 1, 1998

Family Name _____

Given Name _____

Company/Organisation or _____

Community Organisation _____

Media Representatives, tick here ☐

Street and Number _____

City and Code _____

Country _____

Telephone _____ Fax _____

E-mail _____

Accompanying Person's Name _____

ACCOMMODATION

Date of arrival _____ Estimated time _____

Date of departure _____ Number of nights _____

Special requests _____

Please note: A minimum stay of 4 nights is required by all hotels

Arrival by car ☐ train ☐ airplane ☐

REFUND POLICY

- Cancellations received in writing before April 1, 1998 will be fully refunded less CHF 50, administration fee
- After April 1, 1998 no refunds

Rates include service, taxes and breakfast

Category	Single room/night CHF Swiss francs	Double room/night CHF Swiss francs
A	310–355 ☐	380–435 ☐
B	270–310 ☐	320–370 ☐
C	220–260 ☐	260–310 ☐
D	170–210 ☐	200–250 ☐
E	120–160 ☐	140–190 ☐
F (Limited)	80–110 ☐	80–130 ☐

Reservations will be confirmed only upon receipt of your hotel deposit

In case the category I have chosen is fully booked, please book me in the next available higher ☐ lower ☐ category

Transfer of Subtotal CHF _____

TOURS

		No. of persons	Price per person	CHF Swiss francs
Sightseeing Tour *				
Monday June 29	11.00-13.00	_____	30	_____
Tuesday June 30	09.00-11.00	_____	30	_____
Lake Cruise *				
Monday June 29	15.00-17.00	_____	35	_____
Tuesday June 30	15.00-17.00	_____	35	_____
Castle of Chillon *				
Wednesday July 1	09.00-13.30	_____	78	_____
Thursday July 2	09.00-13.30	_____	78	_____
Convent of St. Maurice *				
Wednesday July 1	09.00-18.00	_____	100	_____
Castle of Dardagny and Wine-Tasting *				
Thursday July 2	14.00-17.00	_____	50	_____
Chamonix-Mont Blanc *				
Thursday July 2	09.00-17.00	_____	95	_____
Post Conference Tour *				
Saturday July 4 – Monday July 6		_____	810	_____
Single supplement		_____	50	_____

* Vat 6.5% is included Grand Total CHF _____

Please include a copy of the banker's draft made out to AKM Travel, or a copy of your bank transfer to Union Bank of Switzerland, account No. 595.400.02H WAC or provide a credit card that we can debit. Your name and AIDS 98 should accompany all payments.
Please indicate below which of the following means of payment you have used for accommodation and tours.

Make sure to indicate AKM, AIDS 98 and your name on all money transfers.

Banker's Draft ☐
Bank Transfer (free of charge for recipient) to Union Bank of Switzerland 595.400.02H WAC ☐
Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Diners Club ☐

Credit Card No _____

Expiry date

M	M	Y	Y

 Card Holder's name _____

Date

D	D	M	M	Y	Y

 Card Holder's signatue _____

We regret we are
unable to accept
personal or
company cheques

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.



12th World AIDS
Conference Geneva
June 28–July 3 1998

Scholarship Application

Guide to Scholarship Application

The information you provide on this form is considered confidential and will only be shared with the staff and organisers of the Geneva 98 Conference for the purpose of reviewing and selecting scholarship recipients. Scholarship applicants will be told if they have been selected to receive a scholarship during the month of April 1998.

This Scholarship Programme will help to bring delegates from developing countries, educators, caregivers, health professionals, researchers, community workers and persons living with HIV/AIDS to the 12th World AIDS Conference. The total number of scholarships available is not known at this time but it will be limited. All applicants are therefore strongly advised to seek funding from other sources.

Note that persons who filled out an earlier version of this application form are asked to fill in this form. Those who filled out the previous form, however, will still be considered for a scholarship.

Scholarship Options

Not all of your expenses to attend the Conference will necessarily be paid. In some cases, however, full financial support will be considered.

Please indicate the support you really need:

- ☐ Registration fee
- ☐ Air travel (prepaid ticket at lowest fare)
- ☐ Accommodation (shared or dormitory)
- ☐ Living allowance while in Geneva

Application Procedure

Documents required:

- Completed application form
- A letter of support from your employer, your AIDS organisation, or your support group (with a contact person and telephone number) **must be attached** to your application.
- If you are submitting an abstract, please attach it to your application

APPLICANT INFORMATION (Please print or type)

Family Name _____

Given Name _____

Organisation _____

Your role and duties in that organisation _____

Mailing address

Street and Number _____

City and Code _____

Country _____

Telephone _____ Fax _____

E-mail _____

Courier address (if different from mailing address)

Street and Number _____

City and Code _____

Country _____

Media Registration Form



12th World AIDS
Conference Geneva
June 28 – July 3 1998

Return this form to:
Congrex Sweden AB
Attn: AIDS 98
P.O. Box 5619
SE-114 86 Stockholm
Sweden
Phone: +46 8 459 6600
Fax: +46 8 661 8155

Family Name _____

Given Name _____

Company/Organisation _____

Street and Number _____

City and Code _____

Country _____

Telephone _____ Fax _____

E-mail _____

REGISTRATION	No of pers or items	Price/pers or item	CHF Swiss francs
Media		0	0
Print ☐			
Broadcast ☐			
(credentials required)			
Conference Record (Abstracts) *			
print ☐	_____	50	_____
CD-ROM ☐	_____	50	_____
both ☐	_____	100	_____
* VAT 6,5% is included		Total	_____

VAT No: 410 608
VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm
P.Adr. KPMG Fides
Postfach, Badenerstrasse 172
8026, Zürich, Switzerland

All payments should be made out in CHF (Swiss francs) to Congrex, attn. AIDS 98.
Please indicate which of the following means of payment you have used.

We regret we are
unable to accept
personal, company,
or Eurocheques

Make sure to indicate Congrex, AIDS 98 and your name on all money transfers.

Banker's Draft ☐ Bank: S-E Banken, SE-106 40 Stockholm, Sweden, Account No. 5553-82 242 79 ☐

Visa ☐ American Express ☐ Eurocard/Mastercard ☐ Expiry date _____

Credit Card No _____

Card Holder's Name _____

Date _____

Card Holder's Signature _____

I hereby authorise Congrex to debit this credit card account for the total amount due. I also consent to Congrex debiting or crediting my credit card account with the amount of any subsequent change(s) to the items booked.

Abstract ***Receipt Acknowledgement*** Card

Complete this card to receive an acknowledgement of receipt of your abstract.
Please print your full name and address on the other side so we can mail the card
back to you. Please include this card in the envelope with your Abstract Form.

This is to confirm that we have received your abstract. By April 15, 1998 you will receive
written notice as to whether your abstract has been accepted for either oral or poster
presentation at the 12th World AIDS Conference. In any future communications with
Congrex please refer to your abstract by the number assigned to it below.

Abstract Registration Number
(To be assigned by Congrex)

**12th World AIDS
Conference Geneva
June 28-July 3 1998**



Name _____

Address _____

Country _____

*Abstract Acknowledgement
sent from:*

Congrex Sweden AB
P.O. Box 5619
SE-114 86 Stockholm
Sweden

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

Sustiva - Information For Patients
An Expanded Access Program for
People with HIV-1 Infection

INFORMATION FOR PATIENTS

SUSTIVATM
efavirenz

**AN EXPANDED
ACCESS PROGRAM
FOR PEOPLE WITH
HIV-1 INFECTION**

Call the
SUSTIVA Expanded
Access Program at
1 800 998-6854

DUPONT
PHARMA



**10 Quick & Easy
Condom Substitutes
.... NOT!**

"Just say, 'No!' "

former First Lady Nancy Reagan

It is against the administrative rules, and in most cases the law for prisoners to engage in sexual activity while incarcerated. It's just one of those things that a person is forced to give up when they are in jail or prison. Not only is it against the rules, but it is liable to get you into a *whole* lot of trouble.

Not just with The Man, either. Did you know that in most jails and prisons approximately 28% of all prisoner fights, stabbings and incidents are caused by arguments over sex, sexual favors, sexual partners, relationships, etc. It's a fact. Having said all that, and while **we want you to know that we do not condone, or promote, or advise you to participate in any sort of sexual activity while incarcerated**, we know it happens like clockwork. This pamphlet details some of things desperate prisoners have tried in the past when no condoms are available. They seldom work, are dangerous to your health and safety, and do not provide any real barrier against the transmission of any sexually transmitted disease (STD), of which HIV/AIDS, hepatitis, and herpes are but a few.



The absolute best, and really the only way to protect your self from being put in the cross and at higher risk for HIV/AIDS, hep, herpes, TB, the clap, etc., is to abstain.



- Do not participate in *any* sexual activity at all, while incarcerated. Save it for when you go back to the streets.

- When you are free**, and participating in any sexual activity that is not entirely safe, take all precautions that you can to protect you, your family, and those around you from disease transmission.



- Have sex only with one partner. Make sure you and your partner have been tested for HIV, TB, hepes, and hepatitis, and that you both are negative. Women **and** men, gays **and** straights, adults **and** juveniles ... **all** races **and** religions are at risk for and get STD's!


- ALL THE TIME AND EVERY TIME**: Use latex barriers properly with non-oil-based lubricant, do not trade bodily fluids, clean your works, do not share needles. Remember, there are barriers for the penis, the vaginal **and** anal openings, **and** the mouth!

- Be careful if you tattoo or pierce to be sure that the person who is giving you the piercing or tattoo is using clean and safe needles, machines, ink, and procedures.



If you don't care enough about you to keep yourself healthy and operating in peak condition, no one else is going to do it for


you! Part of that caring is being smart. Don't listen to that Yard gossip. Don't go fer the okie-doke. There are some out there who will tell you that it's not really a risky thing for you to have sex without protection - or while locked up. Okay, and if you believe that... I know this officer who will let you scale the fence right under the guard tower, too...



Then there are those who will tell you that it doesn't matter, ... *just this once!* It matters, each time, every time. Protection and safer sex practices are the only way to be safe. There are those who will tell you that they have something on hand which is just as good as a condom. Well, nothing is just as good as a condom. Abstinence is *better* than a condom! But that's it. So, here's the real deal on what you are probably hearing out there and why it's a bogus wire.

#1 Cut the finger off of a latex medical or search glove.

Well, they may look like a condom, sort of; but they aren't.




They are not designed for the rough give and take that comes along with anal sex. They are not made the same way as a condom, and they have no collar to seal at the end of the shaft of the penis. There is no way to keep the glove finger on the penis. Using a rubber band to secure it can injure you for good! They slip off too easily, Some people *reuse* them!..... *really* a bad idea!!

#2 Use a modified external male catheter.



Lots of jails and prisons have male prisoners who are in need of external catheters due to a number of medical conditions. The word is that you can get one of these catheters, which look a little like rubbers, take off the hard rubber connector, tie a knot in the end, melt it down with a match or lighter to make sure its tight, roll it up and use it like a rubber with a 'french tickler' on the end of it. The latex rubber is too thick, there are cases where the same one has been used 20 or 30 times, the melting of the tip weakens the structure of the latex, promoting tearing, if you don't melt it, the knot is liable to come untied during sex, defeating the purpose.






#3 Use a piece of plastic sandwich or kitchen wrap as a dental dam or condom.

Jail and prison food service operations often use plastic sandwich wrap for box lunches, or in the kitchen. Some people have tried getting pieces of this wrap, washing it off, drying it out, and using it as a dental dam (a device to protect the mouth during oral sex) or as a vaginal or anal dam. Some people have tried to use plastic wrap as a condom substitute. It seems pretty obvious that it's a real measure of last resort. Not much better than no protection at all. There is nothing to keep the wrap secured around the shaft of the penis or in the oral cavity. If you are using a rubber band or tape, or something else to keep the plastic on, it can hurt you, or tear skin when it is removed. The wrap can stretch or tear easily. When used as a dental dam, in the mouth, there is a *real* danger of you inhaling the plastic and choking to death on it if it gets caught in your wind pipe. When used in the vagina or anus, there is nothing in the dam itself to help it keep its shape. It can collapse, and become lodged in the orifice. Not a good thing.

#4 Cut open a latex glove or use the palm of it as a vaginal or rectal condom.

Again with the latex glove bit, already! This time from a slightly


different perspective. Female prisoners have need of latex barriers as well. There are special latex condoms which are designed to be inserted into the vaginal cavity or into the rectum. They often cost as much as twenty times as much as a regular male condom. There have been reports of women using latex gloves which have been cut open across the palm, the fingers taken off, and the material made into a rough square. Then it is inserted into the vaginal or rectal cavity. Males have been known to use the glove as a rectal and dental dam as well. The problem is that the pieces are ill-shaped and not designed for the use they are being put to. They do not form a seal, there is little or no *real* protection, and they can be difficult to take out. In some cases infections and tissue tears and bleeding have resulted from this use.



No woman or man would want to go to Sick Call and ask someone to take a wad of latex filled with... *whatever* out of their vaginal or rectal cavity, or throat/mouth.

#5 Use an empty cigarette pack or Bugler cellophane liner as a barrier substitute.

Things are pretty damned desperate when you have to resort to using an empty cigarette or Bugler cellophane wrapper instead of going to the store and getting a condom. Is there ever *anything* that is *that* urgent?? It's cellophane, thin plasticine. Not latex. It is no shield. Some people swear by this substitute in a pinch, but there is just about *nothing* that it will keep in or out.... The wrapper has to be secured in place by tape to even have a ghost of a chance and that tape



can tear skin, cause rashes, or even cause quicker leaks in the cellophane. By far the better idea is to plan ahead, be responsible, and carry a *real* condom with you. If you find yourself without a condom, either get one (available for free from an HIV/AIDS service center, or a Planned Parenthood-type organization), or for less than a buck at drug or adult stores..... or wait!



#C Use a candy bar wrapper:


Candy packet wrappers are primarily manufactured from wax or plastic coated paper. In some cases they are extruded stretch plastic. In the case of the coated paper models..... they are just that, coated paper. Paper is no barrier. Even paper that has been coated with wax or plastic. There is no way to keep the packet around the shaft of the penis. Tape is ineffective because it causes

the packet to rip and deteriorate. The packet is not meant to take the punishment of sexual activity and will not retain fluids, or act as a barrier from fluid or virus transfer. In the case of the plastic packets, the material is rough, has sharp edges and can cut the tender tissue within the vaginal and/or anal cavity, or in the mouth if it is used as a dental dam. It blocks almost total sensation from the nerve endings in the head of the penis and the vagina, can become dislodged from the shaft of the penis and stuck within the vaginal or anal cavity, and cause additional problems. This is *not* protection, this is desperation. This is stupid.

Trim and use a potato chip or snack bag.

Most snack and chip bags these days are made out of thin extruded plastic film. The edges of a bag, once cut and fitted around a penis or to block either the vaginal or anal cavity, or the mouth, remain sharp and dangerous. There have been cases where the use of snack bags has caused anal and vaginal tearing to occur (and subsequent bleeding) which is exactly what you *don't* want to happen! This material does not hold a shape easily, and if it is molded or held in the mouth does not make a particularly effective barrier for anything!





#11 Scotch tape it!

There are a number of institutions and a couple of states where condoms are made available to prisoners in a variety of ways. Other institutions are beginning to investigate providing condoms. In one such institution where condoms had been available, they ran out one day. We received information that some enterprising inmate-clerk decided to seize the moment and make a couple of bucks by selling scotch tape to other prisoners on the line to use until more condoms were dispensed. While this might actually work in a pinch - if the tape were surgical or other medical tape; tape that is designed for holding paper together does *not* usually make the mark when it comes to skin! Besides, you'd have to deal with making a pouch for the sperm to be held in, and the seams of tape don't stay together very well! Why not just wait for later?

#12 Use an envelope from some old mail you got.

We get a lot of mail, mostly from prisoners in large city or county facilities, a good number of juveniles, and sometimes from INS and other in-transit locations telling us that the sex still goes on, and they know they need to try to be safe. There is often no way to access any mainline institution services, and contact with any permanently housed population is limited. So, we hear frequent tales where prisoners wanting to protect themselves, and being without anything else, have used envelopes of personal mail of some sort to try and make due! Then they wonder if it will work.... are they safe? Was it enough?..... It's paper, people! It is going to

leak, it offers almost totally **ZERO** protection, and your valuable mail may be lost or damaged as a result. It appears that many of you women and men know that there **is** such a thing as safer sex, and that you *can* protect yourself. Now, let's work on knowing what equals 'protection', and when it's better to decide not to go for it.



#13 Cut and modify a package liner from the Store Room or Commissary.

Lots of goods come packaged in large boxes, or on pallets which are covered with some kind of flexible plastic. Some of it has actually had a pretty good rep with some prisoners as far as making a so-so emergency substitute for a condom, vaginal, dental or anal dam. The thing to remember is that often times this material is not as safe as it appears. *It can be and often is porous.* The virus, and other STD's can make it through the 'barrier'. And all the other concerns about keeping its shape, having sharp or rough edges which can cause tissue injury and bleeding, etc. holds true. We receive lots of letters from women wondering how effective modified liners and packaging can be. It appears to be a fairly common choice for many people. We can only urge you to stop and think: this tuff is meant to keep boxes and stuff together. It is **not** intended to be used to protect against things such as a virus or a bacteria which are microscopic, and have varying chemical make-ups! Things like *ph balance* and acidity and other factors can make what you are trying to do useless! Please..... be careful out there!

Some final thoughts.....

The job of educating prisoners, their families, and those who work around them about safer sex and condoms is just beginning. From the reaction we get, it is an very emotionally charged subject. Not just in a correctional setting, but in schools, on the streets, everywhere. Don't expect any quick or easy solutions regarding the issue, **or** for condoms! There just aren't any...

Condoms are and have been made available to prisoners in some jails and prisons in the U.S. for a while now. There are solid figures which indicate that sex is not more prevalent, that HIV and other STD infection rates go down, and money (and life) is saved. The bottom line is that it is **your** responsibility, and the responsibility of the person you may have sex with to care enough about your life, your health, and your safety to know when to say, "No thanks, I'll pass right now!". For the record, we think that you should say that **every** time, and **all** the time as long as you are locked down.

Do your time, go home, and get on with your life. Protect yourself, protect your family, protect those you may have sex with in the future. There **are** no quick and easy condom substitutes!

Artwork by David Flores

For information about HIV/AIDS, TB, and other infectious disease in corrections, prevention education, case management, call for your closest office of

CHC

The Correctional HIV Consortium

1525 Santa Barbara Street, #1

Santa Barbara, CA 93101

voice (805) 568-1400

or

(800) 572-9310

fax: (805) 564-4381

e-mail: chc@silcom.com

web site: <http://www.silcom.com/~chc>

Michael in Geneva

[June 27 - July 5]

hotel -- Domaine de Chateauvieux

41-22-753-1511

41-22-753-1924 (fax)

1

**Schedule
Itinerary**

2

Logistical Fact Sheet

3

**Conference Map
Geneva Map
Office Map**

4

**Office Supplies
Bios/Press Clips**

5

CDC Media Briefing

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

1

Divider Title: _____

Travel Schedule

July 26th

3:30 PM Car pick up from 736 Jackson en route Dulles Airport, Delta Terminal

6:10 PM Delta Airlines/Austrian Air Flight #2772, Seat 18D (aisle)
Departing Washington Dulles en route Zurich

Note: Michael Iskowitz is in seat 17D

July 27th

8:25 AM Arrive Zurich, Terminal A

9:50 - 10:35 AM Delta Airlines/Swissair Flight #2686, Seat 25D (aisle)
Departing Zurich, Terminal A en route Geneva

July 4th

2:40 - 4:05 PM United Airlines/Lufthansa Flight #3717, Seat unassigned
Departing Geneva, Main Terminal en route Frankfurt, Terminal 1

5:50 - 8:25 PM United Airlines Flight #977, Seat 16G
Departing Frankfurt, Terminal 1 en route Washington Dulles

Emergency Travel: 800-847-0242 Code: KC52

Contact List

Sandra Thurman & Todd Summers

<u>Name</u>	<u>Org.</u>	<u>Numbers</u>	<u>Hotel Accomodations</u>		<u>Notes</u>
Avrett, Sam Gold, David	AVAC	P: 310-4045 F: 310-4039	Hotel Touring-Balance		AVAC Members can also be contacted through Bill Snow @ (415) 864-8609
Baker, Corne.	NAPWA	P: 41 22 798-7575	Movenpick Hotel		
CDC	CDC Press Office	P: 41 22 799-2083	Zurich 2 at the Swissair/JATA Centre, 33 route de l'aéroport, 1215 Geneva- Airport		Media Releases Information You can also pick them up off of the web @ www.cdcnac.org/geneva98
Di Donato, Paul	FCAA	P: 41 22 792-0411 F: 41 22 792-0546	Hostellerie de la Vendee 28, ch. de la Vendee/CH-1213 Geneve/ Petit-Lancy		Todd - Dinner on Saturday night
Gooden, Roger		P: 1 22 731-3400	Hotel Crystal 41 22 731-3400		From Kansas City trip
Goosby, Eric	HHS	Hotel P: 4122 908-9081 Rm. 7767 Office P: 41 22 761-1240			
Holewinski, Sa	ONAP	HP: (202) 588-5476 OP: (202) 395-1441 NP: (301) 598-1839			Home phone, Office phone, Nana phone (call me anytime anywhere)
Jackson, Linda	OAR	P: (301) 402-3357			Logisitical questions/information
Martin, Marsha	HHS	P: 0 22 908-9081 F: 0 22 908-9090	Noga Hilton Geneva 19, Quai du Mont-Blanc, 1211 Geneva 2		
Montoya, Daniel	PACHA	P: 41 22 919-3939 F: 41 22 919-3838	Hotel Intercontinental Geneve 7-9 Chemin du Petit Saconnex, Gen. 19		Will be on vacation from July 4 - July 17th Emergency only: (703) 830-6641
Santiago, Luis	AVAC	P: 22 734-3003	Hotel les Nations		
Sanville, Jane	ONDCP	P: 41 22 798-7575 F: 41 22 791-0284	Hotel Movenpick Route de Pre-Bois 20, CH-1215 Gen. 15		
Shriver, Mike	NAPWA	P: 41 44 731-6750	Hotel Drake 6/24-25 Movenpick Hotel 6/26 - 7/3		

June						
S	M	T	W	T	F	S
1	2	3	4	5	6	
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30				


Weekly Schedule

June 28 - July 04, 1998

		28 Sunday	29 Monday	30 Tuesday	1 Wednesday	2 Thursday	3 Friday	4 Saturday
8	:00							
	:15							
	:30							
AM	:45							
9	:00	9:00 AM - 10:00 AM UNAIDS/AVAC Prestrn						
	:15							
	:30							
AM	:45							
10	:00							
	:15							
	:30							
AM	:45							
11	:00							
	:15							
	:30							
AM	:45							
12	:00	12:00 PM - 2:00 PM Trinatl. Lunch Forum						
	:15							
	:30							
PM	:45							
1	:00							
	:15							
	:30							
PM	:45							
2	:00							
	:15							
	:30							
PM	:45							
3	:00							
	:15							
	:30							
PM	:45							
4	:00							
	:15							
	:30							
PM	:45							
5	:00							
	:15							
	:30							
PM	:45							
6	:00		6:00 PM - 7:30 PM NCIH Recpt			6:00 PM - 8:00 PM FCAA Recptn		
	:15					6:15 PM - 8:00 PM Women's Satellite Session		
	:30							
PM	:45							
7	:00		7:00 PM FHI Recpt		7:00 PM - 8:30 PM IAVI Call for Action/ Vaccines			
	:15		7:00 PM - 9:00 PM NMAC Recptn					
	:30							
PM	:45							
8	:00							
	:15							
	:30							
PM	:45							
9	:00							
	:15							
	:30							
PM	:45							
10	:00							
	:15							
	:30							
PM	:45							

Schedule at a Glance

12th World AIDS Conference 1998



Monday June 29 – Thursday July 2

08.00–18.30

Poster Sessions

11.00–20.00

Skills Building Sessions

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

2

Divider Title: _____

Your
Registration
Number
Is
9658



12th World AIDS
Conference Geneva
June 28 - July 3 1998

Todd Summers
Social & Scientific Systems
7101 Wisconsin Avenue
Suite 1300
BETHESDA, MD 20814

UNITED STATES

Your registration number is: 9658

Fax no.

Stockholm May 20, 1998

We are pleased to confirm your registration for the 12th World AIDS Conference to be held in Geneva, Switzerland, June 28 - July 3, 1998.

On-site check-in will be open from Friday, June 26, 1998, at 08.00 and will take place at Palexpo, in the main entrance hall. There will be a shuttle bus service between the Airport and Palexpo on Sunday, June 28, 1998, between 08.00 and 20.00. On-site check-in will be organised by registration number as shown on this confirmation. Remember to bring the confirmation letter to Geneva as you will need it to receive your Conference badge, bag and documents. Without the confirmation letter you will be requested to present proof of identification.

At the time of printing of the Second Announcement, plans for production of the post-conference CD, to contain copies of most slides presented at the Conference, were still incomplete. Please refer to the enclosed flyer for further information and order form.

Please check to confirm that the registration information below is correct.
More information on the Conference is available on Internet: <http://www.aids98.ch>

We look forward to welcoming you in Geneva.

Registered for:	No. of pers	Price p/p	Total CHF
Registration fee before February 2, 1998	1	940,00	940,00
Membership IAS, paid CHF 50	1	0,00	0,00
Conference Record version not chosen	1	0,00	0,00

Total Events	940,00	Debit Total	940,00
VAT incl. with	0,00	Received	940,00
		Balance	0,00

CONGREX SWEDEN AB

POSTAL ADDRESS Attn. AIDS 98, P. O. Box 5619 SE-114 86 Stockholm Sweden

VISITING ADDRESS Linnégatan 89 A

VAT No: 410 608

VAT representative:
Congrex Sweden AB
SE-114 86 Stockholm

12th World AIDS Conference
Geneva, Switzerland

Logistical Fact Sheet for Mr. Summers

Conference Venue:

Palexpo Conference Centre, Exhibition Halls and Arena
(Located at the Geneva Airport)
P.O. Box 112
CH-1218 Grand-Saconnex
Geneva, Switzerland
Telephone: +41 22 798 1111
Facsimile: +41 22 798 0100
Telex: 422784

Conference Dates and Times:

Registration for the conference will open on Saturday, June 27 from 8:30 a.m. to 8:00 p.m. and on Sunday, June 28 from 8:30 a.m. to 4:00 p.m. The conference will officially begin on Sunday, June 28 with the Opening Ceremony from 4:00 p.m. to 6:00 p.m. The conference will conclude on Friday, July 3 with the Closing Ceremony from 12:30 p.m. to 1:30 p.m.

Hotel Accommodations:

Hôtel Intercontinental Genève
P.O. Box 1211
7-9 Chemin du Petit Saconnex
Geneva 19, Switzerland
Tel: +41 22 919 39 39
Fax: +41 22 919 38 38
Telex: 412921

A room has been reserved for you for check-in on June 27 and check-out on July 4. Should your itinerary change, please call Ms. Linda Jackson at (301) 402-3357. Our on-site staff will meet you in the lobby of the Intercontinental and assist you with check-in at the hotel. You will be able to check-in when you arrive. These rooms and tax have been pre-paid. ➡ (Please do not include the hotel room on your travel orders.) You are responsible for payment of your incidental expenses upon check-out of the hotel. The hotel accepts all major credit cards.

When you arrive at the hotel we will provide you with an access card which will give you the PHS telephone/fax numbers, pertinent conference telephone numbers, cellular phone/pager numbers and other various contact information.

Communications:

The Swiss telephone system is an analog system as in the United States, but the telephone wall jacks do not accept the standard U.S. plug (RJ11), which is common on most modem-to-wall-jack adapter cords. You may obtain a Swiss adapter cord at most major hotels in Geneva from the front desk staff. These adapters will also be available at the PHS Office located on the Palexpo Conference Grounds, in the Villa Sarasin. For those using the U.S. Robotics PC Card modem-to-wall-jack adapter, you must bring a coupler to connect the cord into the Swiss adapter. Also, most hotels in Geneva use a "pulse" rather than tone system for dialing. Please contact your LAN system administrator to configure your modem setup to dial in this manner. Tone dialing will be available at the PHS Office in the Villa Sarasin.

Registration:

You have been registered for the Conference, and the registration fee of CHF 940 (U.S. \$657) per person has been paid. ➡ **(Please do not include the registration fee on your travel orders.)** Your conference materials will be delivered to your hotel room when you arrive.

On-Site Offices:

The office that is reserved for ONAP is located in the Villa Sarasin, which is located adjacent to the east end of the Palexpo on the Chemin Sarasin. It is a 5-minute walk from the Palexpo. This office will be available to you on Sunday, June 28, from 2:00 p.m. to 8:00 p.m. and Monday, June 29, through Thursday, July 2, from 7:30 a.m. to 8:00 p.m. and on Friday, July 3, from 7:30 a.m. to 12:00 noon. The telephone number for the VIP reception desk, which is located in the foyer on the Ground Level of the Villa Sarasin, is **+41 22 761 12 50**. The VIP fax number is **+41 22 761 12 76**. Please use these numbers for any messages you wish to receive. We are arranging to have a daily newspaper and copies of Current Clips delivered to this office daily.

Continental Breakfast and Lunch will be provided for you in the ONAP office at 12:00 noon starting Monday, June 29, through Thursday, July 2. ➡ **(Please do not include these meals on your travel orders, if you choose to accept them.)** Please let us know if you are not interested in having these meals provided for you. If there will be additional individuals joining you for lunch, please inform the on-site staff so that arrangements may be made. Money will need to be collected on-site for additional lunches.

Opening Ceremony:

Special seating arrangements has been requested for you during the Opening Ceremony, which will take place on Sunday, June 28, from 4:00 p.m. to 6:00 p.m. Transportation to the Opening Ceremony will be provided. More information about VIP seating will be provided to you upon your arrival in Geneva.

On-Site Appointment Schedule:

Ms. Linda Jackson will be happy to maintain an on-site appointment schedule for you during the conference. If you wish Ms. Jackson to provide this service, please advise her of any appointments you have already made and any future appointments you plan to make.

Entry Documents:

All U.S. citizens traveling to Switzerland must present a valid passport upon entry into Switzerland. A visa is not required. While in Geneva lost or stolen passports must be reported immediately to the U.S. Consular Agency in Geneva at 798 16 15 or 16 05. The Consular Agency is located in the World Trade Center, Building 2, 29 Route de Pré-Bois in Geneva.

Customs/Immigration:

Please note that passengers arriving into the United States from any foreign destination will have to go through U.S. Immigration and Customs at their point of entry into the United States.

Traveling with Medications:

Individuals traveling to and from Switzerland are allowed to carry any medication that has been prescribed by a physician. Please make sure that all prescription medications are kept in the original containers that have the prescription on the label, and if possible, carry a letter from your physician stating you are under his/her care and providing a list of the medications that have been prescribed for you.

Ground Transportation:

Staff members from SSS will greet you at the airport and will provide transportation to the hotel. It will take approximately 5-minutes to reach the hotel. The Palexpo is approximately another 5-minute trip from the hotel. Transportation will also be provided for your return trip to the airport on the day of your departure. Additional information will be provided as the date approaches.

VIP Airport Lounge:

When you arrive at the Geneva International Airport for your return trip to the United States, you will be escorted to the VIP lounge where you may wait until boarding time.

PHS Service Desk:

Villa Sarasin
Chemin Sarasin
Ground Level

Limited office support and equipment are available at the PHS Service Desk. Support includes word processing, faxing, and copying. Equipment includes computers, printers, telephones, and limited audiovisual.

The Villa Sarasin is located at the east end of Palexpo-approximately a 5-minute walk from the main entrance. The PHS Service Desk is located on the Ground Level of the Villa Sarasin and will be open from Sunday, June 28, through Friday, July 3. The office hours on Sunday will be 2:00 p.m. to 8:00 p.m. and Monday through Thursday from 7:30 a.m. to 8:00 p.m. and on Friday from 7:30 a.m. to 12:00 noon. **The telephone number for the PHS Service Desk is +41 22 761 12 40. The fax number is +41 22 761 17 25.**

Time Difference:

Geneva is 6 hours ahead of Washington, D.C.

Language:

The prevalent language spoken in and around Geneva is French, although most people in these areas speak English as well. Outside of Geneva, the majority of the country speaks one dialect or another of German.

Electricity:

The electrical current in Switzerland is 220 volts, 50 cycles. Wall outlets take a Continental-type plug with two round prongs. You will need to bring a converter and an adapter with you if you are planning on using high-wattage appliances, i.e., computer, hair-dryer, etc.

Climate:

June and July in Geneva are usually relatively warm and sunny with temperatures staying between 75° and 80° F. The evenings will be a little cooler.

Tipping:

Tips for porters and doormen are usually around 2 CHF per bag. Tipping in restaurants range from 1 to 2 CHF for a moderate lunch to 5 to 10 CHF for a evening meal. Even in restaurants where the menus are marked that service is included ("service compris"), a light tip is appropriate.

Exchange Rate:

As of May 11, 1998, the exchange rate is U.S. \$1.00 = CHF 1.488.

Currency Exchange:

The most favorable exchange rate will be given at a bank, although there are exchange booths at the airport and rail stations. Cirrus, Plus, and other automated teller machines operate also at the airport and in locations around the city.

Useful Telephone Numbers:

Police.....	117
U.S. Consulate.....	798 16 15
Cointrin (Geneva's Airport).....	799 31 11
Taxis.....	794 74 11 or 321 22 23

Contact Information:

If you have any questions regarding the arrangements that have been made on your behalf, please call Ms. Linda Jackson at (301) 402-3357 prior to June 22. After June 23, Ms. Jackson may be reached at the Hotel Mövenpick Geneva at telephone: + 41 22 798 75 75; fax: + 41 22 791 02 84.

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

3

Divider Title: _____

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

4

Divider Title: _____

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

White House Note Cards
(blank)

THE WHITE HOUSE

IAVI Executive Summary

'Scientific Blueprint for AIDS Vaccine Development'

Executive Summary

Introduction

This *Scientific Blueprint* lays out a detailed global scientific program to put AIDS vaccine development efforts on the fast track. The goal is to identify an AIDS vaccine as soon as possible.

The need for an AIDS vaccine is compelling and urgent. In the past two years, this issue has received a notable increase in international attention. The resources and academic talent devoted to the field of HIV vaccine research is growing. However, efforts to accelerate product development and clinical testing to identify an effective vaccine have not kept pace. The vaccine development pipeline has been likened, appropriately, to a pipette. Few novel vaccine designs have entered clinical trial in the past two years. No efficacy trial of a candidate vaccine has been initiated anywhere in the world, although the first efficacy trial is scheduled to begin in June 1998.

In sum, the world is not on track to meet the bold goal set by the U.S. President, Bill Clinton, to identify a safe and effective vaccine by the year 2007. Further, the effort to ensure worldwide applicability of and access to an AIDS vaccine, once developed, remains largely unattended.

The International AIDS Vaccine Initiative (IAVI) is dedicated to ensuring the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. IAVI believes that the goal of identifying an effective HIV vaccine can be achieved in the shortest period of time if additional resources are applied to vaccine development and clinical trials, including the design, development and test-

ing of vaccines for developing countries. Specifically, we believe that multiple efficacy trials of different vaccine approaches around the world must begin within the next four years in order to achieve our goal. The purpose of this *Scientific Blueprint* is to explain the rationale behind IAVI's strategy of increasing support for scientific projects, particularly those more applied and developmental in nature. This document also proposes a new model for international collaboration in HIV vaccine development.

There Is an Urgent Need that Is Possible to Meet

A vaccine is the only way we will end this epidemic, and most scientists now agree that a safe and effective vaccine to stop AIDS is possible. Despite progress in prevention interventions and the advent of powerful drug combinations to treat HIV infection, approximately 16,000 people become infected every day, 90% of whom live in developing countries. An effective vaccine, given prior to exposure to HIV, would help the body control HIV and prevent AIDS and/or transmission of HIV to others. A vaccine that is effective in all high-risk populations worldwide against all circulating HIV isolates is the best hope for halting the AIDS epidemic.

The Current Multiprong Approach Needs More Prongs

There have been tremendous advances in our understanding of HIV's basic biology. This progress has resulted in large part from the support of national research programs, which generally support basic and targeted research on HIV, develop clinical trial infrastructures, conduct clinical trials, and train researchers.

A vaccine is the only way we will end this epidemic, and most scientists now agree that a safe and effective vaccine to stop AIDS is possible.

Despite the desire to have a balanced, multiprong approach of research and development of multiple vaccine designs, support for basic research continues to dominate national AIDS programs. While over 25 candidates have moved into clinical trials, only three have advanced into the second phase of clinical testing, and only one has advanced, just recently, to the stage at which efficacy can be determined.

The current product pipeline is flowing slowly, if at all. There are few novel designs entering phase I trials, and fewer still that have been designed for testing and use in developing countries. A rational and thorough approach would be to continue vigorous support for new, potentially improved designs, while at the same time evaluating the most promising of the known vaccine design options and combinations.

Fortunately, there are novel, safe vaccine approaches shown to induce immune responses that could offer protection against AIDS. Those approaches must be developed and moved forward into clinical trials. Those already in clinical trials must also advance.

Almost all designs that have entered human trial have been produced by private sector laboratories, which are generally recognized as the only source of the technical expertise required for vaccine development. This includes construction and formulation of the vaccine for human use, and ensuring that the product is made reproducibly and to acceptable levels of purity, potency, consistency, and stability. Very few manufacturers have been willing to commit to testing multiple vaccine concepts in human trials. The reasons include: the long time frame necessary to accomplish these tasks; the question of whether the product will prove efficacious; the financial risk

associated with manufacturing; and several non-scientific disincentives (*i.e.*, uncertainties about market size, and liability and political concerns).

Further, where corporate sponsorship does exist, candidates are being developed for evaluation and use in the United States and Europe. Only a small number of companies are considering the design of vaccines for testing and use in developing countries.

With few exceptions, national programs do not support activities within the private sector that are necessary to bridge the research and development environments and bring products forward for clinical evaluation. It remains unclear to what extent newer programs—including the Vaccine Center at the U.S. National Institutes of Health (NIH), and the European Union focus on vaccines—will result in the entry of innovative vaccine designs into clinical trials, particularly trials in developing countries.

The urgency of the epidemic demands that all reasonable avenues be explored. A linear, stepwise approach is unacceptable. A more aggressive, multipronged strategy is far more likely to rapidly solve scientific problems and identify promising approaches.

Increased Involvement of Developing Countries Is Essential

Developing countries—in which the need for a preventive HIV vaccine is greatest—have been only peripherally involved in the HIV vaccine development process. A few countries, with the assistance of UNAIDS and/or the U.S. NIH, have been active in preparing sites for the field testing of HIV vaccines. Fewer still (Thailand, Brazil, China, Cuba) have actually conducted a phase I trial of a candidate HIV vaccine,

*The current
product
pipeline is
flowing slowly,
if at all.*

and only one country currently shows evidence of significant contributions to all stages of vaccine development. Thailand is distinct in that it has evaluated multiple designs in phase I/II trials; will initiate an efficacy trial in the coming year; and has multiple, active collaborations designed to advance newer vaccine designs into clinical trial.

Multiple efficacy trials of candidate HIV vaccines will be necessary, and these trials will be best conducted in populations at highest risk. Such populations generally reside in developing countries. Unlike the development of most established vaccines, which were first found efficacious in industrialized countries, achievement of an HIV vaccine will require developing countries to become active and long-term partners throughout the development process.

Further, full involvement of developing countries is the most likely route to ensuring that intellectual property arrangements will be structured to provide accessibility and use of eventual products in locations where they are most needed. Involvement of developing countries in all stages of vaccine development will also allow them to consider and solve, on their own terms, the difficult issues of risk/benefit analysis and ethics.

Scientific Issues that Have Limited Developing-Country Participation Can Be Addressed

This key scientific uncertainty has thwarted trials in developing countries: the continued uncertainty about the relevance of different genetic clades to HIV vaccine development. With few exceptions, manufacturers have based their vaccines on laboratory isolates of clade B HIV, the subtype of HIV that predominates in North America and Europe. A long time frame and com-

mitment to process development and manufacturing accompanies a private company's decision to develop a candidate vaccine. For these reasons, it is difficult, time consuming, and costly for a company to adapt a design to the more recently described "primary isolates" of HIV, or to isolates from other clades of HIV. Nonetheless, a few companies are now developing candidate vaccines based on primary isolates and/or clades that predominate worldwide. Biotechnology companies, which are better positioned for risk taking, have generally been unable to raise the venture capital to support aggressive HIV vaccine-development programs. This is particularly true of designs based on the most prevalent HIV clades.

It may be that the 10 or so genetic clades of HIV will prove irrelevant to HIV vaccine design. Recent evidence has shown that CTLs (immune cells that recognize and destroy cells with signs of HIV infection) isolated from people infected with clade B HIV can kill at least some isolates from at least some other clades. However, "universal killing," in which CTLs kill cells infected with any isolate from all clades, has yet to be described. In addition, while there appear to be conformational epitopes that are shared among the various clades, researchers have yet to design antigens that induce antibodies against those epitopes.

In the absence of definitive knowledge about the immunologic significance of genetic subtypes or a clear definition of immunotypes on which a vaccine can be logically based, candidate vaccines tested in individuals at risk for HIV infection should be based on the HIV subtype(s) that predominate in the proposed trial population. Alternatively, there could be justification to advance to larger trials a "mismatched" vaccine

*Multiple
efficacy trials
of candidate
HIV vaccines
will be
necessary, and
these trials will
be best
conducted in
populations at
highest risk.*

that has been shown to induce strong immune responses in the proposed trial population against the spectrum of viruses that circulate in that population.

However, this approach is potentially time consuming. For example, if the “mismatched” vaccine fails to induce adequate immunity, the question would remain as to whether the vaccine lacked efficacy because of the design itself, or because the design was not based on circulating virus isolates. If new and novel vaccines are to be pursued toward clinical trial, there is no apparent reason why those vaccines should not be based on the HIV subtypes that are most prevalent worldwide.

A “Thoughtful Empiricism” Approach to HIV Vaccine Development—the Rapid, Definitive Testing of Candidate Vaccines—Is Needed

There are significant scientific and technical questions that bring a great deal of uncertainty to the development of HIV vaccines. Foremost among them are the lack of validated correlates of immune protection and the absence of an ideal animal model of HIV disease. While these questions remain, it will not be possible to definitively conclude from small clinical studies or animal studies whether any specific candidate vaccine is effective. Appropriately designed larger clinical trials in humans will be required to determine if and to what extent a vaccine works.

HIV vaccine research and development is at a crossroads. The scientific community could step back and put its full weight behind tackling these basic research obstacles, and move candidate vaccines forward when there is consensus that the vaccine is likely to be protective. This approach might be defensible if the rate of spread of HIV were low or tapering off. However,

worldwide statistics demonstrate otherwise. Further, there are a number of examples in which other vaccines have proven successful without ever knowing the correlate of immune protection, and/or in which an ideal animal model was lacking.

Given the urgency of the epidemic and the failure of other measures to control the spread of HIV, it is time to give significantly more weight to HIV vaccine development. In particular, more human research on more candidate vaccines is needed, including vaccines designed for and tested in developing countries. All reasonable candidate vaccine designs should enter phase I trials to evaluate safety and immunogenicity. The best designs that prove safe and that induce immune responses that could reasonably be argued might be protective should advance into phase II clinical studies in individuals at higher risk for HIV infection, and eventually into larger trials to determine efficacy.

This rapid, definitive testing of candidate vaccines is called “thoughtful empiricism.” Its value is twofold: First, such trials will help identify efficacious vaccines. Second, they will generate immunologic data that can lead to improved vaccine designs. The only truly “failed” trials are those that do not yield useful scientific information.

This process will take years and millions of dollars in addition to what is already being spent on basic and targeted research, and on smaller clinical trials.

A Sense of Urgency Must Prevail

When President Clinton set the goal of identifying an effective vaccine by the year 2007, leaders of the Group of 8 (the world’s largest economies) followed with their own pledge: to provide the necessary resources to accelerate HIV

Involvement of developing countries in all stages of vaccine development will allow them to consider and solve, on their own terms, difficult issues of risk/benefit analysis and ethics.

vaccine research. Leaders from other countries should accept this challenge.

The goal appears to have been largely ignored in the new grant programs heralded by the U.S. NIH and others. National programs have fostered basic research on HIV and HIV vaccine designs, but have not increased the development and clinical trials efforts needed to meet this goal.

The time required for the mandatory preclinical and clinical evaluation of experimental HIV vaccines is quite long, approximately seven to eight years. Unless there is an immediate breakthrough in vaccine design, it is highly unlikely that new basic knowledge will contribute to an effective vaccine by 2007. If an effective vaccine is to be identified by then, only those products already in or near the preclinical stage have any chance of fulfilling the goal. All designs that have shown promise in preclinical and clinical studies should advance through the pipeline as rapidly as possible.

New Models of International Cooperation in HIV Vaccine Development Are Needed

IAVI believes that new mechanisms should be established to foster true international partnerships in HIV vaccine research and development. Toward that end, IAVI has developed a distinctive scientific strategy for the world. Specifically, we propose creation of international product development teams, which would bring together vaccine designers, vaccine developers/companies, and clinical researchers from both industrialized and developing countries to work together on all stages of the development process. Each team would focus on one specific vaccine approach.

This worldwide strategy has been designed to complement, not compete with, existing programs at UNAIDS, NIH, the French National AIDS Research Agency, and other national and international organizations. The approach, at a cost of approximately US\$350 million-\$500 million above current expenditures over the next nine years, emphasizes cooperation with industry and has evolved from extensive consultations with leaders of national and international organizations and industry.

IAVI's strategy is unique in that it focuses exclusively on accelerated product development and testing through international collaborations. The challenge in executing a fast-track HIV vaccine development strategy is to ensure that the most promising new candidate vaccines are tested as rapidly as possible in the best clinical and field study sites. While this tactic may seem obvious, there is no ready mechanism whereby researchers with an exciting new vaccine can identify and establish direct collaborations with clinical and field researchers and populations in epidemic locations.

The need to match vaccine approaches with epidemic locations for testing can be met by creation of international product development teams. This is the concept: Assemble a team of vaccine researchers, manufacturers, and clinical researchers around a candidate vaccine product *before* a pilot lot is produced. In this way, a comprehensive and seamless vaccine development plan can be formulated and adhered to. Such a team should have an international composition because new technical approaches traditionally derive from laboratory research in industrialized countries, while the epidemic locations with the highest incidence of HIV are typically in developing countries. The exact institutional composition of

*IAVI's strategy
is unique in
that it focuses
exclusively on
accelerated
product
development
and testing
through
international
collaborations.*

each team would vary according to the range of expertise among team members. Scientists from the developing country would be expected to work closely with scientists from industry.

Conclusions

Even given the ongoing and planned efforts of the private and public sectors, critical gaps in HIV vaccine development must be filled if an effective vaccine is to be ready within nine years. Foremost among these is the need for enhanced global political commitment to ensure that every promising new vaccine approach is clinically evaluated for safety, immunogenicity, and efficacy as rapidly as possible. Several promising new approaches should be designed for and tested in developing countries hardest hit by HIV and AIDS, and plans should be laid for several phase III efficacy trials.

The urgency of the worldwide AIDS epidemic relative to ongoing vaccine development and clinical-trial efforts begs for creation of new models of international collaboration. Models that include developing-country participation throughout the vaccine-development process have the best chance for success and will best address worldwide needs. Toward this end, IAVI proposes the model of international HIV vaccine product development teams that bring together research, manufacturing, and clinical-trial expertise to accelerate development and evaluation of promising vaccine designs.

*The need to
match vaccine
approaches
with epidemic
locations for
testing can be
met by
creation of
international
product
development
teams.*

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

Trends in the HIV & AIDS Epidemic

- ◇ Turning Point in the Epidemic
- ◇ Magnitude of the Epidemic
- ◇ Trends in HIV Diagnoses in 25 States
- ◇ Historical Trends in AIDS Incidence
- ◇ Implications for Prevention
- ◇ Evaluating the Impact of Treatment
- ◇ A Closer Look by Race and Gender

1998



CDC
CENTERS FOR DISEASE CONTROL
AND PREVENTION